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When the Human Genome Project was launched 25 years ago, the stage was
set for an exciting era in biology and medicine. Pioneering discoveries of the most
fundamental information concerning gene structure, function, and regulation have
furthered our understanding of the role of genetics in health and disease. Technolog-
ical advances in high-throughput sequencing and methods for interpreting large-scale
genetic data are rapidly shaping the breadth of human genetics research. The com-
plexity and diversity of the human genome still presents considerable challenges,
however. We can harness the information from human genetic variation to address
enduring challenges in understanding complex disorders, the motivation for which I
present the following dissertation.
1.1 Population-based association studies
Complex traits are multifactorial, presenting complexities beyond single-gene dis-
orders with classic Mendelian inheritance patterns. The considerable challenges in
understanding complex phenotypes have driven the development of study designs
that rely on comparisons of unrelated affected and unaffected individuals. A genome
wide association study (GWAS) tests the relationship between genetic marker predic-
Modified from: Schmidt and Willer (2015)
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2tors across the genome and a single case-control or quantitative phenotype response
by employing logistic or linear regression, respectively. Typically, each study partic-
ipant is genotyped for a set of genome-wide independent markers on a commercial
genotyping array. In humans there are stretches of DNA that segregate together more
often than is expected by chance, resulting in non-independent markers in linkage
disequilibrium (LD). To address multiple testing and LD properties, a typical GWAS
considers one million independent single nucleotide polymorphisms (SNPs), result-
ing in a Bonferroni significance cut-off of association P -value ≤ 5x10-8. Increasing
sample sizes provide greater power to detect associations at the genome-wide level.
Currently, there are catalogued over 10,000 single markers that reach genome-wide
significance for hundreds of phenotypes (Welter et al., 2014).
A major consideration in the design of case-control GWA studies is the choice
of a control group. For a trait with high prevalence for example, it is important
to carefully choose healthy matched controls rather than picking a random sample
of control individuals from the population. GWAS designs involving quantitative
traits should ensure that the trait is normally distributed, which often requires a
logarithmic or inverse normal transformation of the trait before association testing.
Appropriately adjusting for confounders such as age and sex can also be critical to
prevent spurious or false positive associations and to maximize power. Population
structure presents another challenge that is typically accounted for using principle
components (Price et al., 2006) or mixed-model approaches (Kang et al., 2010).
We expect association P -values that deviate from the null uniform distribution to
represent true positive associations. Inflation from the null distribution indicates
additional batch effect or population structure that was not accounted for in the
association analysis, and suggests that false positive results may be present. Test
3statistics can be inflated by a factor lambda (λ), which is defined as the ratio of
the median of the observed distribution of the test statistic to the median of the
expected distribution (0.455, χ2df=1) (Devlin and Roeder, 1999). Genomic control
adjustment by this lambda reduces inflation and the risk of false positive associations.
With careful study design including consideration of confounding factors, GWAS is
a powerful tool to discover true causal relationships in which genetic marker alleles
or nearby linked alleles influence susceptibility.
Genome-wide screening for single marker associations is generally used for iden-
tifying common variation (minor allele frequency (MAF) > 5%), but loses power in
efforts to identify associations with low frequency (0.5% < MAF ≤ 5%) or rare (MAF
≤ 0.5%) variants. Protein-coding variants with deleterious function are likely to be
rarer in the human population due to natural selection acting against them, and
have mostly arisen recently in evolutionary history (Fu et al., 2013). Because of the
rare nature of most variants with functional consequence, studies carefully designed
to uncover rare variant associations are crucial (Lee et al., 2014; Zuk et al., 2014).
Recent advances in exome sequencing and exome array technologies have facilitated
larger and more accurate studies for interrogating the protein-coding 1-2% of the
genome. However, single variant association tests commonly used by GWAS carry a
heavy multiple testing burden and still lack power when applied to rare variants of
high impact. Additional challenges for finding rare variation using traditional GWAS
single-variant approaches include poor coverage on arrays and difficulties with im-
puting. Thus, aggregation-based tests that group multiple variants by a single gene
or functional unit have become standard for rare variant association testing.
Several regression-based approaches have been developed in recent years to op-
timize rare variant discovery. In a simple burden test, multiple rare variants are
4collapsed into a genetic score representing the cumulative effect of those variants
in a single unit. Then, the score is tested for association with a trait or disease.
This idea, which has been implemented by numerous investigators (Morgenthaler
and Thilly, 2007; Li and Leal, 2008; Madsen and Browning, 2009; Morris and Zeg-
gini, 2010; Asimit et al., 2012), assumes that all variants in a single unit are causal
and that all alleles affect the phenotype with the same magnitude and direction of
effect. More robust modifications of a simple burden test introduce adaptive weights
or thresholds (Han and Pan, 2010; Hoffmann et al., 2010; Liu and Leal, 2010; Price
et al., 2010; Ionita-Laza et al., 2011; Lin and Tang, 2011). We can account for the
protective or deleterious impact of alleles on phenotype by considering the magni-
tude and direction of effect using variance-component tests (Pan, 2009; Neale et al.,
2011; Wu et al., 2011). Finally, we can combine burden and component tests (Lee
et al., 2012; Derkach et al., 2013; Sun et al., 2013) or score statistics (Chen et al.,
2012) to achieve more robust power. Choosing the optimal strategy for grouping
rare variants is flexible and may depend on the genetic architecture of a particular
trait (Ladouceur et al., 2012).
Meta-analysis is a powerful tool to jointly analyze GWA datasets from multiple
studies, especially when individual-level data are not available (Chapman et al.,
2011). In fact, the statistical power achieved by meta-analysis of summary statistics
is quite comparable to that achieved from the cumbersome pooling of individual-
level data (Lin and Zeng, 2010). Fisher’s method (Fisher et al., 1970) for combining
P -values is one simple method, but it neither weights by sample size nor considers
magnitude or direction of effect. This approach is impractical when individual studies
are unequal in size and/or the number of studies becomes large. We can combine
evidence for association by converting P -values into a signed Z -score weighted by
5sample size, or by weighting effect size estimates by their estimated standard errors
(Stouffer et al., 1949; Willer et al., 2010). When studies provide score statistics
for each variant and a variance-covariance matrix, a fixed-effects meta-analysis will
achieve improved power (Hu et al., 2013; Lee et al., 2013; Liu et al., 2014).
The association findings from GWAS provide an initial guide for the develop-
ment of medical treatments by pointing to a genomic region of interest. Within a
single locus however, there may be several or more genes and hundreds of linked ge-
netic variants. Identifying the putative causal variant and unraveling the underlying
functional mechanism at a single locus often requires finer interrogation and experi-
mental follow-up. Given the non-independent nature of markers across the genome,
it is common to only genotype a subset of independent markers in a GWA study.
However, commercial SNP genotyping panels only assay a small fraction of variants
that contribute to complex disease. Meta-analysis of multiple GWA studies by as-
signing SNPs genotyped in one study as proxies for SNPs genotyped in another study
is complicated. Genome sequencing is more comprehensive, but can be expensive for
studies involving thousands of participants. Imputation provides a cost-effective in
silico strategy for accurately guessing un-typed markers without directly genotyping
every variant across the genome (Marchini et al., 2007; Li et al., 2010). Under the
assumption that unrelated individuals share short stretches of haplotypes inherited
from distant common ancestors, we can use a subset of typed markers measured in
only one individual to impute into another. Targeted dense genotyping of carefully
selected loci is an effective follow-up strategy, as demonstrated by arrays such as
Metabochip (Voight et al., 2012a) and Immunochip (Cortes and Brown, 2011) that
are tailored for trait-specific follow-up.
61.2 Insights into plasma lipids from genetic discovery
Cardiovascular disease is the leading cause of death in the United States and
throughout the world, representing a significant human health burden (Mozaffarian
et al., 2015). Genetic studies of lipid levels, known risk factors for heart disease
with heritability ranging from 40% to 60% in humans (Weiss et al., 2006), are logical
targets in efforts to prevent and treat heart disease. Modulation of these quantitative
lipid traits, which include low-density lipoprotein cholesterol (LDL-C), high-density
lipoprotein cholesterol (HDL-C), triglycerides (TG), and total cholesterol (TC), can
be effective therapeutically. Lipid traits are not independent, making it challenging
to untangle the effects of specific lipids on disease risk. LDL-C and TC generally
act in the same direction of effect on heart disease risk since the majority of TC is
composed of LDL-C. In addition, high TG is associated with high LDL-C and low
HDL-C, while LDL-C and HDL-C are positively and inversely associated with heart
disease risk, respectively (Emerging Risk Factors Collaboration et al., 2009).
Much of our current understanding of the genetics of blood lipids and impli-
cations in human health has originated from genome-wide association discoveries.
Early GWA studies with modest sample sizes (<10,000) uncovered common variants
(MAF>5%) with large effect sizes (Kathiresan et al., 2008; Willer et al., 2008). The
power to discover new lipid-associated variants increased with sample size (Kathire-
san et al., 2009; Teslovich et al., 2010). In Chapter II, I describe a joint meta-analysis
of nearly 180,000 samples which uncovered 62 novel independent genetic loci con-
taining lipid-associated variants (Global Lipids Genetics Consortium et al., 2013).
Most of the associated variants are non-protein-coding, suggesting a regulatory role
(Welter et al., 2014). An illustration of the regulatory role of a noncoding LDL-
7C-associated variant is evident at the SORT1 locus. Researchers demonstrated in
human-derived hepatocytes that variant rs12740374 at an LDL-C-associated GWAS
locus creates a C/EBP transcription factor binding site, causing altered expression
of the nearby SORT1 gene (Musunuru et al., 2010). Still, common variants generally
have limited functional consequence.
Common variants identified by GWAS explain only a fraction (∼20-25%) of the
heritable trait variance for lipids (Teslovich et al., 2010). In effort to explain some of
the missing heritability, we turn to low frequency and rare variation. The Common
Disease-Rare Variant hypothesis proposes that the combined effect of a number of low
frequency variants with large effect sizes accounts for some of the missing heritability
(Pritchard and Cox, 2002). Indeed, early sequencing studies of candidate genes
supported the contribution of multiple rare alleles to plasma HDL-C levels (Cohen
et al., 2004).
Mendelian family studies involving large pedigrees are valuable for rare variant
genetic studies. In this design, the co-segregation of variants among affected fam-
ily members can be traced. Investigators recently used whole-exome sequencing in
a multi-generation family to uncover a rare variant in a highly conserved codon of
SLC25A40 that is associated with TG, giving insight into a previously unknown bi-
ological mechanism of hypertriglyceridemia (Rosenthal et al., 2013). My subsequent
focus will include findings from large-scale array and sequencing studies for complex
lipid traits.
Interrogating the protein-coding genome through re-sequencing coding regions
(Kryukov et al., 2009) and whole-exome sequencing (Do et al., 2012) can reveal rare
mutations with a large effect on phenotype. A splice variant in APOC3 associated
with TG was identified using whole-genome sequencing, representing one of the first
8rare variants of large effect to be found using this sequencing approach at the popu-
lation scale (Timpson et al., 2014). Sequencing the exome is more cost-effective than
whole-genome sequencing, however, and fewer statistical tests are performed, reduc-
ing the multiple testing burden. The potential of exome sequencing has resulted in
studies powered for the discovery of novel rare variation implicated in blood lipids.
For example, investigators of the National Heart, Lung, and Blood Institute Exome
Sequencing Project used exome sequencing to identify the burden of rare variants
in four genes (PNPLA5, PCSK9, LDLR and APOB) significantly associated with
LDL-C (Lange et al., 2014). By contrast to modest effect sizes observed from indi-
vidual SNPs identified by GWAS, the burdens of rare variants in these genes have
substantially higher effect sizes (Figure 1.1). Association testing using the more
cost-effective study design of genotyping and successfully imputing SNPs has also
led to novel insights into the impact of rare variants on lipids (Surakka et al., 2015).
Tables 1.1 and 1.2 summarize the contribution of low frequency and rare variation
to lipids from single variant and burden tests, respectively.
The exome chip custom genotyping array allows for large-scale efficient genotyping
of low frequency coding variants with large effect sizes. Exome wide association
studies for lipids and related diseases revealed several significant variants at both
established and previously unknown lipid loci. Rare variants at ANGPTL4, LIPC
and LIPG, for example, were found to be associated with TG and HDL-C (Holmen
et al., 2014) (Table 1.1). In addition, a more common variant in the protein-coding
gene, TM6SF2, was found to be associated with total cholesterol and myocardial
infarction risk (Holmen et al., 2014; Kozlitina et al., 2014). Functional follow-up
revealed that modulation of Tm6sf2 in mice alters lipid levels, providing the causal
gene at a GWAS locus that was previously intractable for follow-up due to a large
9number of genes in the associated region. These findings illustrate the value of
interrogating changes in the exome in guiding our exploration of the functional gene
at lipid loci.
Because we expect that rare variants of large effects are more likely to occur in
coding regions, detection of rare noncoding variants with comparable effect sizes will
generally require much larger sample sizes. Whole-genome sequencing of nearly 1,000
individuals revealed more about the genetic architecture of HDL-C (Morrison et al.,
2013). Morrison et al. (2013) found that common variation explains a whole 61.8%
of the trait heritability for HDL-C, and individuals with extreme HDL-C harbor
rare variants with large effect sizes. Dense genotyping on custom arrays can guide
discovery of rare functional variants that were not previously interrogated and help
narrow the association signal (Sanna et al., 2011; Wu et al., 2013). Fine mapping on
Metabochip in Europeans highlighted the LDL-C associated rare R46L (p.Arg46Leu)
variant (allele frequency 0.03) at PCSK9 to refine the GWAS signal (Global Lipids
Genetics Consortium et al., 2013). In addition, methods to evaluate enrichment of
noncoding variants in regulatory regions of the genome will give insight into the
biological mechanisms involved and help prioritize rare functional variants (Lo et al.,
2014; Schmidt et al., 2015).
1.3 Translation of plasma lipid levels to disease risk
Understanding the relationship between plasma lipid concentrations and heart
disease risk is paramount in addressing human health. Several lipid loci contain
variants associated with risk for diseases such as coronary artery disease (CAD)
(CARDIoGRAMplusC4D Consortium et al., 2013), highlighting the causal role of
blood lipids on CAD. Although the correlation between increased triglyceride levels
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and increased risk of CAD is well established (Sarwar et al., 2007), the causality
of this relationship is a separate question that has claimed recent attention. After
adjusting for the effects of both LDL-C and HDL-C, Do et al. (2013) found correlation
between the effect size of TG-associated SNPs and the magnitude of the effect on
CAD risk, suggesting causality. Exome sequencing revealed a set of rare variants,
including one missense and 3 loss-of-function driver mutations in APOC3 associated
with low plasma TG (TG and HDL Working Group of the Exome Sequencing Project,
National Heart, Lung, and Blood Institute et al., 2014). Carriers of such mutations
showed significantly reduced risk for CAD.
Although the causal relationship between low LDL-C and reduced risk for myocar-
dial infarction (MI) is well established and used in treatment (Baigent et al., 2005),
the causality of high HDL-C with a similar outcome has been challenged (Voight
et al., 2012b). A Mendelian randomization study (n >25,000 participants) involving
a low frequency variant p.Asn396Ser (allele frequency 0.026) in LIPG that is associ-
ated with high HDL-C showed that carriers did not have a significantly reduced risk
for MI (Voight et al., 2012b). This questions the utility of high plasma HDL-C to
either predict or treat heart disease.
Researchers sequenced the exons of the NPC1L1 gene and found naturally occur-
ring mutations that can mimic the activity of an LDL-C lowering drug and thus re-
duce coronary heart disease (CHD) risk (Myocardial Infarction Genetics Consortium
Investigators et al., 2014). Low frequency variants in PCSK9 are also known to be as-
sociated with low LDL-C and reduced CHD risk (Cohen et al., 2005, 2006; Cohen and
Hobbs, 2013). This prompted the interrogation of rare coding variation to find simi-
lar occurrences elsewhere in the genome. Using an exome array, researchers identified
four low-frequency variants associated with HDL-C (in ANGPTL8, PAFAH1B2, and
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PCSK7 ) and TG levels (in COL18A1 ), but not CHD (Peloso et al., 2014) (Table 1.1).
Lipid loci demonstrate a significant degree of pleiotropy, in which a single locus can
result in multiple phenotypes. Figure 1.2 illustrates the pleiotropic nature of lipid-
associated loci, many of which were discovered in studies described in this thesis.
This complexity introduces challenges for translation to human health, presenting
motivation for human genetics research of complex traits. Studies of heritable vari-
ation will be instrumental in guiding physicians toward appropriate risk prevention,
diagnosis, and treatment of cardiovascular disease.
1.4 Interpreting noncoding genetic variation
Understanding the underlying biology of noncoding human genetic variation and
translating association findings into clinical practice remains a universal challenge.
In contrast to protein-coding mutations that cause an amino acid change to poten-
tially alter protein function, noncoding variation typically acts by altering the DNA
sequence to which transcription factors (TF) and other proteins bind. Changing TF
binding affinity can affect gene expression levels, thus contributing to phenotypic vari-
ation. The noncoding nature of most trait-associated variation identified by GWAS
suggests that these polymorphisms play an important role in transcriptional regula-
tion (Hindorff et al., 2009). To understand this, we can explore epigenomic changes
across the genome such as histone modifications and DNA methylation that impact
gene expression levels by changing chromatin structure. High throughput technolo-
gies have allowed us to investigate protein interactions with DNA through chromatin
immunoprecipitation followed by massively parallel DNA sequencing (ChIP-Seq).
The information about protein binding sites together with noncoding trait-associated
variation from GWAS provides further insight into the mechanisms acting to alter
12
phenotype (see Chapter III).
Several large-scale efforts such as the National Institutes of Health Roadmap Epig-
nomics Project (Roadmap Epigenomics Consortium et al., 2015) and the National
Human Genome Research Institute ENCODE Project (ENCODE Project Consor-
tium, 2012) have been launched with the goal of developing a comprehensive cata-
logue of all human genomic functional elements. The data generated by these public
repositories are key to addressing the challenges of interpreting noncoding variation.
We can harness the heritable nature of drug response to explore the genetic mech-
anisms of noncoding mutations contributing to drug response variability. For exam-
ple, genetic variation within regulatory elements can disrupt TF binding and drug
response by altering a drug-targeted affinity. This concept has been demonstrated by
Soccio et al. (2015), showing that variants within binding sites of PPARγ, a nuclear
receptor target for anti-diabetic therapy, alter PPARγ and cofactor occupancy. This
in turn alters response to the drug rosiglitazone, demonstrating a new mechanism by
which noncoding variation leads to drug response variability. Still, the heterogene-
ity in drug response remains a major challenge facing physicians when prescribing
treatment.
1.5 Discovery of structural variation
The complexity of the human genome extends beyond single nucleotide polymor-
phisms and indels to larger structural variation that can span thousands of bases.
This class of variation presents unique challenges in discovery and functional interpre-
tation. Structural variation (SV) historically refers to chromosomal rearrangements
of >1 kb in size, but due to sequencing technologies broadening the spectrum of
discovery, can now be expanded to events of >50 base pairs (bp) in length (Alkan
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et al., 2011). Structural variants can be balanced or unbalanced, changing the num-
ber of base pairs in the genome and thus referred to as copy number variants (CNVs).
Pang et al. (2010) estimates that CNVs within a single genome result in 1.2% dif-
ference from the consensus reference sequence. In contrast to ∼83% of the total
detected genetic variation in gene expression that results from SNPs, CNVs capture
∼17% (Stranger et al., 2007). Mills et al. (2011) found 22,025 deletions and 6,000
additional SVs including insertions and tandem duplications in 185 sequenced hu-
man genomes. The latest 1000 Genomes Project effort discovered and genotyped
∼14,000 large deletions (48bp-995kb) in a diverse set of over 1,000 sequenced indi-
viduals (1000 Genomes Project Consortium et al., 2012). The Database of Genomic
Variants archive (DGVa) catalogues structural variant data in a public repository
for dissemination to the wider research community (http://www.ebi.ac.uk/dgva).
Methods of detecting structural variation have evolved with changing technology
and study designs. Early studies used hybridization-based technologies such as ar-
ray CGH (comparative genomic hybridization) to capture CNVs (Iafrate et al., 2004;
McCarroll et al., 2008; Conrad et al., 2010). Although microarrays are cost-effective,
they are low throughput and low resolution technologies that cannot identify bal-
anced structural variants. Advances in next generation sequencing (NGS) technolo-
gies and the routine use of genome- and exome-sequencing data sets have allowed
us to call complex events with unprecedented resolution. For NGS-based discovery,
mapped sequence reads are compared to a reference genome to find patterns that
can be classified into various SV types such as deletions, duplications, inversions,
and translocations.
There are a number of NGS-based computational approaches for SV discovery,
all of which present bioinformatics challenges and each with its own set of strengths
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and weaknesses (Mills et al., 2011; Alkan et al., 2011). The read-pair mapping ap-
proach compares the consistency of orientation of read pairs to a reference genome,
and can detect most classes of variation. Discordantly matched paired-ends with an
alignment distance, or insert size, that deviates significantly from the expected dis-
tance on the genome are used to estimate SV coordinates (Korbel et al., 2007; Chen
et al., 2009). Another method observes significantly higher or lower read depth com-
pared to a random distribution of mapping depth to call duplications or deletions,
respectively (Yoon et al., 2009). A split-read method identifies the exact break-
point of a structural variant by observing regions where the read alignment to the
genome is broken (Ye et al., 2009). GenomeSTRiP integrates read-depth, read-pair,
and split-read approaches for discovering and genotyping deletions in a population
(Handsaker et al., 2011, 2015). Another SV caller, DELLY, combines read-pair and
split-read analysis for calling both balanced and unbalanced events (Rausch et al.,
2012). Lastly, de novo assembly of contigs that are compared to a reference genome
can be used to discover various classes of SVs (Zerbino and Birney, 2008; Li, 2015).
When various NGS-based SV discovery approaches are directly compared on a dis-
tinct set of samples, the number of events called uniquely by a single method is as
high as 80% of all SVs discovered by that method (Mills et al., 2011; Alkan et al.,
2011). This comparison illustrates the complementary nature of these various dis-
covery techniques. In addition, there are sensitivity vs. specificity trade-offs among
popular tools, and a comparison of their performance on calling deletions over 100 bp
reveals false negative rates ranging from 0.31 to 0.79 and false positive rates ranging
from 0.09 to 0.37 (Li, 2015).
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1.6 Functional impact of structural variation in complex disorders
Our current understanding of the role of structural variation in health-related phe-
notypes is limited relative to less complex forms of genetic variation. Indeed, SVs are
known to contribute to many disease types ranging from Mendelian disorders (e.g.
Charcot-Marie-Tooth Disease (Lupski et al., 1991)) to sporadic developmental syn-
dromes (e.g. autism (Sebat et al., 2007)) to common complex disease (e.g. psoriasis
(Hollox et al., 2008), systemic lupus erythematosus (Yang et al., 2007)).
Genome-wide association studies, used primarily for identifying associations be-
tween SNPs and quantitative traits or disease phenotypes, are less commonly im-
plemented for association with structural variation. Our ability to sequence large
numbers of individuals and accurately call and genotype SVs has made genome-wide
SV associations more informative. Discovery and association analysis of the func-
tional impact of structural variation in myocardial infarction (MI) from whole genome
sequencing is the subject of Chapter IV. Previous discovery of SV’s using array CGH
found common copy number variants that are well tagged by trait-associated SNPs,
presenting plausible functional candidates (Conrad et al., 2010). For example, Con-
rad et al. (2010) identified a CNV in LD (r 2=1) with an MI-associated single variant
(rs6725887) at the WDR12 locus first reported by Myocardial Infarction Genet-
ics Consortium et al. (2009). With the improved resolution of SV detection from
sequencing technologies, we can develop a more comprehensive map of structural
variation to better understand the genetic landscape of complex disease.
1.7 Dissertation outline
My research objective is to understand how human genetic variation causes phe-
notypic differences and individual disease risk, even when only a small fraction of
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this variation is protein-coding. The subsequent chapters explore multiple facets of
human genetic variation to further our understanding of the genetic landscape of
quantitative lipid traits and cardiovascular disorders. From single genetic variants
with a focus on understanding noncoding transcriptional regulation to structural
variation classified from whole genome sequencing, this work contributes important
insights into complex disease and will help tailor strategies for translation to human
health.
Novel lipid-associated variants with small effect sizes can be identified
at genome-wide significance through targeted genotyping of additional in-
dividuals on Metabochip followed by meta-analysis with the original lipids
GWAS results. In Chapter II, I describe the largest genome-wide meta-analysis
for lipids to date, involving nearly 100,000 additional participants phenotyped for
lipids and genotyped on Metabochip. I report 62 novel genetic loci associated with
lipids and through various downstream bioinformatics analyses, provide evidence for
the biological relevance of these loci to help inform potential functional follow-up.
Because of the noncoding nature of most trait-associated variants iden-
tified by GWAS, including those associated with lipids examined in Chap-
ter II, I hypothesize that a majority are involved in transcriptional regu-
lation rather than altering protein function to induce phenotypic change.
I develop the open source tool GREGOR (Genomic Regulatory Elements and Gwas
Overlap AlgoRithm) to quantify enrichment of trait-specific GWAS variants in reg-
ulatory features. I find evidence of enrichment of lipid-associated variants in regula-
tory features in liver, and see analogous enrichment of other trait-associated variants
in features of biologically relevant tissues. This method, described in Chapter III,
gives further insight into the mechanisms of transcriptional regulation by which trait-
17
associated variants are acting. In addition, I evaluate regulatory feature overlap of
linked variants at a set of individual lipid-associated loci to hypothesize the func-
tionality of particular variants, and present experimental results to support my com-
putational predictions.
Lastly, I hypothesize that there are different frequencies of genomic
structural variants in myocardial infarction cases compared to controls
and apply established and complementary SV detection algorithms to
identify and genotype deletions, duplications, and inversions. Chapter IV
examines the functional impact of structural variation on MI through whole genome
sequencing in a Norwegian sample, and provides the results of genome-wide associ-

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 1.1: Power to detect lipid-associated loci for different study designs. Dotted lines represent
80% power curves and points represent lipid-associated loci from sequencing (Lange et al., 2014;
Timpson et al., 2014) (red), exome chip (Holmen et al., 2014) (blue), and GWAS (Global Lipids
Genetics Consortium et al., 2013) (black) study designs. Colored loci in red represent standardized
effect sizes and burden frequencies estimated from European American or British samples (Lange
































































































































































































Figure 1.2: Effects of lipid-associated loci on related phenotypes. Effect sizes were obtained from
Global Lipids Genetics Consortium et al. (2013) (HDL-C, LDL-C, TC, TG), Locke et al. (2015)
(BMI, body mass index), International Consortium for Blood Pressure Genome-Wide Association
Studies et al. (2011) (DBP and SBP, diastolic and systolic blood pressure), CARDIoGRAMplusC4D
Consortium et al. (2013) (CAD, coronary artery disease), Morris et al. (2012) (T2D, type 2 dia-
betes), and Scott et al. (2012) (FG, fasting glucose). Blue and red colors represent positive and
negative direction of effect, respectively; gray represents not significant after Bonferroni correction
for 157 independent lipid loci (P>0.0003); white represents missing data.
CHAPTER II
Metabochip meta-analysis for discovery and refinement of
genetic loci associated with plasma lipid levels
2.1 Abstract
Levels of low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein
cholesterol (HDL-C), triglycerides (TG) and total cholesterol (TC) are heritable,
modifiable risk factors for coronary artery disease. To identify new loci and refine
known loci influencing these lipids, we examined 188,577 individuals using genome-
wide and custom genotyping arrays. We identify and annotate 157 loci associated
with lipid levels at P<5x10-8, including 62 loci not previously associated with lipid
levels in humans. Using dense genotyping in individuals of European, East Asian,
South Asian and African ancestry, we narrow association signals in 12 loci. We find
that loci associated with blood lipid levels are often associated with cardiovascular
and metabolic traits, including coronary artery disease, type 2 diabetes, blood pres-
sure, waist-hip ratio and body mass index. Our results demonstrate the value of
using genetic data from individuals of diverse ancestry and provide insights into the
biological mechanisms regulating blood lipids to guide future genetic, biological and
therapeutic research.




Blood lipids are heritable, modifiable risk factors for coronary artery disease
(CAD) (Kannel et al., 1961; Castelli, 1988), a leading cause of death (Lloyd-Jones
et al., 2010). Human genetic studies of lipid levels can identify targets for new ther-
apies for cholesterol management and the prevention of heart disease and can com-
plement studies in model organisms (Teslovich et al., 2010; Barter and Rye, 2012).
Studies of naturally occurring genetic variation can proceed through large-scale as-
sociation analyses focused on unrelated individuals or through the investigation of
mendelian forms of dyslipidemia in families (Rahalkar and Hegele, 2008). We previ-
ously identified 95 loci associated with blood lipids, accounting for ∼10-12% of total
trait variance (Teslovich et al., 2010), and showed that variants with small effects can
indicate pathways and therapeutic targets that enable clinically important changes
in blood lipid levels (Teslovich et al., 2010; Musunuru et al., 2010).
Here we report on studies of naturally occurring variation in 188,577 European-
ancestry individuals and 7,898 non-European-ancestry individuals. Our analyses
identify 157 loci associated with lipid levels at P<5x10-8, including 62 new loci.
Thirty of the 62 loci do not include genes implicated in lipid biology by previous
literature. We tested lipid-associated SNPs for association with mRNA expression
levels, carried out pathway analyses to uncover relationships between loci and com-
pared the locations of lipid-associated SNPs with those of genes and other functional
elements in the genome. These results provide direction for biological and therapeu-
tic research into risk factors for CAD.
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2.3 Results
2.3.1 New loci associated with blood lipid levels
We examined subjects of European ancestry, including 94,595 individuals from
23 studies genotyped with genome-wide association study (GWAS) arrays (Teslovich
et al., 2010) and 93,982 individuals from 37 studies genotyped with the Metabochip
array (Voight et al., 2012a) (Figure 2.1). The Metabochip includes variants rep-
resenting promising loci from our previous GWAS (14,886 SNPs) and from GWAS
of other CAD risk factors and related traits (50,459 SNPs), variants from the 1000
Genomes Project (1000 Genomes Project Consortium et al., 2010) and focused rese-
quencing (Sanna et al., 2011) efforts in 64 previously associated loci (28,923 SNPs)
and fine-mapping variants in 181 loci associated with other traits (93,308 SNPs). In
cases where Metabochip and GWAS array data were available for the same individ-
uals, we used Metabochip data to ensure that key variants were directly genotyped
rather than imputed.
We excluded individuals known to be on lipid-lowering medications and evaluated
the additive effect of each SNP on blood lipid levels after adjusting for age and sex.
Genomic control values (Devlin and Roeder, 1999) for the initial meta-analyses were
1.10-1.15, low for a sample of this size, indicating that population stratification should
have had only a minor impact on our results (Figure 2.2). After genomic control
correction, 157 loci associated with blood lipid levels were identified (P<5x108),
including 62 newly associated loci (Figure 2.3, Tables 2.1, 2.2, 2.3, and 2.4). Loci
were>1 Mb apart and nearly independent (r 2<0.10). Of the 62 newly associated loci,
24 demonstrated the strongest evidence of association with HDL cholesterol levels,
15 demonstrated the strongest evidence of association with LDL cholesterol levels,
8 demonstrated the strongest evidence of association with triglyceride levels, and 15
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demonstrated the strongest evidence of association with total cholesterol (Figure 2.4).
Several of these loci were validated by a similar extension based on published Global
Lipids Genetics Consortium GWAS results (Asselbergs et al., 2012).
The effects of newly identified loci were generally smaller than in earlier GWAS
(Figure 2.5). For the 62 newly identified variants, trait variance explained in the
Framingham offspring was 1.6% for HDL cholesterol levels, 2.1% for triglyceride
levels, 2.4% for LDL cholesterol levels and 2.6% for total cholesterol levels.
2.3.2 Overlap of genetic discoveries and previous knowledge
To investigate connections between our new loci and known lipid biology, we first
catalogued genes within 100 Kb of the peak associated SNPs and searched PubMed
and Online Mendelian Inheritance in Man (OMIM) for occurrences of these gene
names and their aliases in the context of relevant keywords. After manual curation,
we identified at least 1 strong candidate in 32 of the 62 loci (52%) (Tables S2.1
and S2.2). For the remaining 30 loci, we found no literature support for the role
of a nearby gene in regulating blood lipid levels. This search highlighted genes
whose connections to lipid metabolism have been extensively documented in mouse
models (such as VLDLR and LRPAP1 (Welch et al., 1996)) and human cell lines
(such as VIM (Sarria et al., 1992)), as well as candidates whose connection to lipid
levels is more recent, such as VEGFA. With respect to the latter, recent studies of
VEGFB have suggested that vascular endothelial growth factors have an unexpected
role in the targeting of lipids to peripheral tissues (Hagberg et al., 2010), which we
corroborate by associating variants near VEGFA with blood triglyceride and HDL
cholesterol levels.
Multiple types of evidence supported several literature-identified candidates (Ta-
bles S2.3 and S2.4. For example, VLDLR is categorized by Gene Ontology (GO)
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(Ashburner et al., 2000) in the retinoid X nuclear receptor (RXR) activation path-
way, which also includes genes (APOB, APOE, CYP7A1, APOA1, HNF1A and
HNF4A) in previously implicated loci (Teslovich et al., 2010). However, because
these additional sources of evidence build on overlapping knowledge, they are not
truly independent.
To estimate the probability of finding ≥32 literature-supported candidates after
automated search and manual review of results, we repeated our text-mining litera-
ture search using 100 permutations of SNPs matched for allele frequency, distance to
the nearest gene and number of proxies in linkage disequilibrium (LD). To approx-
imate manual curation of the text-mining results, we focused on genes implicated
by 3 or more publications (25 in observed data, 8.7 on average in control SNP sets,
P=8x108).
2.3.3 Pathway Analyses
We performed a gene set enrichment analysis, using MAGENTA (Segre` et al.,
2010) to evaluate the over-representation of biological pathways among associated
loci. Across the 157 loci, MAGENTA identified 71 enriched pathways. These path-
ways included at least 1 gene in 20 of our newly identified loci. Examples included
DAGLB (connected to previously associated loci by genes in the triglyceride lipase
activity pathway), INSIG2 (connected to previously associated loci by the choles-
terol and steroid metabolic process pathways), AKR1C4 (connected to previously
associated loci by the steroid metabolic process and bile acid biosynthesis pathways),
VLDLR (connected to previously associated loci by the retinoic X receptor activation
and lipid transport pathways, among others) and PPARA, ABCB11 and UGT1A1
(three genes assigned to pathways implicated in the activation of nuclear hormone
receptors, which have an important role in lipid metabolism through the transcrip-
27
tional regulation of genes in sterol metabolic pathways (Fitzgerald et al., 2002)). Of
the 16 loci where literature review and pathway analysis both suggested a candidate,
the predictions overlapped 14 times (Tables S2.3 and S2.4; by chance, we expected
6.6 overlapping predictions; P=1x105).
2.3.4 Protein-protein interactions
We assessed evidence for physical interactions between proteins encoded near our
associated SNPs using DAPPLE (Rossin et al., 2011). We found an excess of direct
protein-protein interactions for genes in loci associated with LDL cholesterol levels
(ten interactions; P=0.0002), HDL cholesterol levels (eight interactions; P=0.002)
and total cholesterol levels (six interactions; P=0.017) but not for triglyceride levels
(two interactions; P=0.27). Most of the interactions involved genes at known loci
(such as the interaction network connecting PLTP, APOE, APOB and LIPC ) or
highlighted the same genes as the literature and pathway analyses (such as those
connecting VLDLR, APOE, APOB, CETP and LPL). Among the new loci, we iden-
tified a link between AKT1 and GSK3B. GSK3B has been shown to have a role in
energy metabolism (Plyte et al., 1992), and its activity is regulated by AKT1 through
phosphorylation (Toker and Cantley, 1997). Literature review also supported a role
in the regulation of blood lipid levels for these two genes.
2.3.5 Regulation of gene expression by associated variants
Many variants associated with complex traits act through the regulation of gene
expression. We examined whether our 62 newly identified variants were associated
with the expression levels of nearby genes in liver, omental fat or subcutaneous fat.
Fifteen variants were associated with the transcript levels of a nearby gene at a
significance of P<5x10-8 (Table S2.5), and seven lipid-associated variants were in
28
strong LD (r 2>0.8) with the strongest expression quantitative trait locus (eQTL)
for the region (r 2>0.8). In three of these loci, literature searches also prioritized
candidate genes. In all three, eQTL analysis and literature review identified the
same candidate (DAGLB, SPTLC3 and PXK ; P=0.05). For the remaining four
loci (near RBM5, ADH5, TMEM176A and GPR146 ), analysis of expression levels
identified candidates that were not supported by literature or pathway analyses.
2.3.6 Coding variation
In some loci where previous association studies of coding variants were incon-
clusive, we now found convincing evidence of association, demonstrating the ben-
efits of the large sample sizes achievable through collaboration. For example, in
the APOH locus (Kaprio et al., 1991), our most strongly associated variant was
rs1801689 (APOH p.Cys325Gly; P=1x10-11 for LDL cholesterol levels). Overall, at
15 of the 62 new loci, there was at least 1 nonsynonymous variant within 100 kb
of and in strong LD (r 2>0.8) with the index SNP (Table S2.6) (18 loci when there
was no restriction on distance). This ∼30% overlap between associated loci and
coding variation is similar to that for other complex traits (1000 Genomes Project
Consortium et al., 2010). Unexpectedly, in the 11 loci where a candidate was sug-
gested by literature review and by examination of coding variation, the candidates
from these methods coincided 7 times (P=0.03 compared to the expected overlap by
chance of 3.8 times); thus, agreement between literature review and examination of
coding variation was less significant than for eQTL studies and analyses of pathways
or protein-protein interactions.
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2.3.7 Overlap between association signals and regulators of transcription in liver
Despite our efforts, 18 of the 62 newly identified loci remain without prioritized
candidate genes. The liver is an important hub of lipid biosynthesis, and there is
evidence that lipid-associated variants might be associated with changes in gene reg-
ulation in liver cells (Ernst et al., 2011). Using Encyclopedia of DNA Elements
(ENCODE) data (ENCODE Project Consortium, 2011), we evaluated whether as-
sociated SNPs overlapped experimentally annotated functional elements identified
in HepG2 cells, a commonly used model of human hepatocytes. To determine sig-
nificance, we generated 100,000 lists of permuted SNPs matched for minor allele
frequency (MAF), distance to the nearest gene and number of SNPs in LD (r 2>0.8)
(Section 2.5.12). In HepG2 cells, lipid-associated SNPs were enriched in 8 of the 15
functional chromatin states defined by Ernst et al. (2011) (P<1x10-5; Table S2.7).
The strongest enrichment was in regions with ‘strong enhancer activity’ (3.7-fold
enrichment; P=2x10-25; Table S2.8). In the other eight cell types examined by Ernst
et al. (2011), no more than three functional chromatin states showed evidence for
enrichment (and, when present, enrichment was weaker).
We proceeded to investigate the overlap between lipid-associated loci and func-
tional marks in HepG2 cells in more detail Table S2.8). Notable regulatory elements
showing significant overlap with lipid-associated loci included histone marks associ-
ated with active regulatory regions (acetylation of histone H3 at lysine 27 (H3K27ac),
P=3x10-20; acetylation of histone H3 at lysine 9 (H3K9ac), P=3x10-22), promoters
(trimethylation of histone H3 at lysine 4 (H3K4me3), P=2x10-15; dimethylation of
histone H3 at lysine 4 (H3K4me2), P=8x10-12), transcribed regions (trimethyla-
tion of histone H3 at lysine 36 (H3K36me3), P=4x10-14), indicators of open chro-
matin (FAIRE (formaldehyde-assisted isolation of regulatory elements), P=5x10-9;
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DNase I sensitivity, P=2x10-4) and regions that interact with the transcription fac-
tors HNF4A (P=6x10-10) and CEBP/B (P=1x10-5). Overall, 56 of our 62 new loci
contained at least 1 SNP that overlapped a functional mark (ENCODE Project Con-
sortium, 2011) and/or chromatin state (Ernst et al., 2011) highlighted in Table S2.8,
including all but 3 of the loci where no candidates were suggested by literature review
or analyses of pathways, coding variation or gene expression.
2.3.8 Initial fine mapping of 65 lipid-associated loci
Previous fine mapping of five LDL cholesterol-associated loci found that variants
with the strongest association were often substantially different in frequency and
effect size from those identified by GWAS (Sanna et al., 2011). Metabochip genotypes
enabled us to carry out an initial fine-mapping analysis for 65 loci: 60 selected for fine
mapping on the basis of our previous study (Teslovich et al., 2010) and 5 nominated
for fine mapping because of association with other traits.
For each of these loci, we identified the most strongly associated Metabochip
variant and evaluated whether it (i) reached genome-wide significant evidence for
association (to avoid chance fluctuations in regions where the signal was relatively
weak) and (ii) was different from the GWAS index SNP in terms of frequency and
effect size (operationalized to r 2<0.8 with the GWAS index SNP). In the European
samples, fine mapping identified eight loci where the fine-mapping signal was clearly
different from the GWAS signal (Table S2.9). The two largest differences were at the
loci near PCSK9 (top GWAS variant with MAF (f )=0.24, P=9x10-24; fine-mapping
variant with f =0.03, P=2x10-136) and APOE (GWAS variant f =0.20, P=3x10-44;
fine-mapping variant f =0.07, P=3x10-651), consistent with results from Sanna et al.
(2011). Large differences were also observed near LRP4 (GWAS f =0.17, P=8x10-14;
fine-mapping f =0.35, P=1x10-26), IGF2R (GWAS f =0.16, P=7x10-9; fine-mapping
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f =0.37, P=2x10-13), NPC1L1 (GWAS f =0.27, P=2x10-5; fine-mapping f =0.24,
P=1x10-12), ST3GAL4 (GWAS f =0.26, P=2x10-6; fine-mapping f =0.07, P=6x10-11),
MED1 (GWAS f =0.37, P=3x10-5; fine-mapping f =0.24, P=2x10-10) and COBLL1
(GWAS f =0.12, P=2x10-6; fine-mapping f =0.11, P=6x10-9). Thus, although the
large changes observed by Sanna et al. (2011) after fine mapping are by no means
unique, they are not typical. Except for the p.Arg46Leu variant encoded in PCSK9,
the variants showing the strongest association in fine-mapped loci all had MAF>0.05.
We also attempted fine mapping in samples with African (n=3,263), East Asian
(n=1,771) and South Asian (n=4,901) ancestry. Despite comparatively small sample
sizes, ancestry-specific analyses identified associated SNPs clearly distinct from the
original GWAS variant in five loci (Table S2.9). These loci included APOE, consistent
with the analyses in individuals of European ancestry, three loci where differences in
LD between populations enabled fine mapping in samples of African (SORT1 and
LDLR) or East Asian (APOA5 ) ancestry and CETP, where an African ancestry-
specific variant was present. For CETP, SORT1 and APOA5, results are consistent
with those of other fine-mapping and functional studies (Musunuru et al., 2010;
Buyske et al., 2012; Palmen et al., 2008).
2.3.9 Association of lipid-related loci with metabolic and cardiovascular traits
To evaluate the role of the 157 loci identified here in related traits, we evalu-
ated the most strongly associated SNPs for each locus in genetic studies of CAD
(n=114,590 including 37,653 cases) (Schunkert et al., 2011; Coronary Artery Disease
(C4D) Genetics Consortium, 2011), type 2 diabetes (T2D; n=47,117 including 8,130
cases), (Voight et al., 2010) body mass index (BMI; n=123,865 individuals) (Speliotes
et al., 2010) and waist-hip ratio (WHR; n=77,167 individuals) (Heid et al., 2010),
systolic and diastolic blood pressure (SBP and DBP; n=69,395 individuals) (Inter-
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national Consortium for Blood Pressure Genome-Wide Association Studies et al.,
2011) and fasting glucose levels (n=46,186 non-diabetic individuals) (Dupuis et al.,
2010). We observed an excess of SNPs nominally associated (P<0.05) with all these
traits, including a 5.1-fold excess for CAD (40 nominally significant loci; P=2x10-19),
a 4.1-fold excess for BMI (32 loci; P=1x10-11), a 3.7-fold excesses for DBP (29 loci;
P=1x10-9), a 3.4-fold excess for WHR (27 loci; P=1x10-9), a 2.5-fold excess for SBP
(20 loci; P=1x10-4), a 2.3-fold excess for T2D (18 loci; P=0.001) and a 2.2-fold
excess for fasting glucose levels (17 loci; P=3x10-3). Interestingly, for the new loci,
we observed greater overlap with BMI, SBP and DBP (nine overlapping loci each)
than with CAD (eight overlapping loci). Of the new loci, the two SNPs showing the
strongest association with CAD mapped near RBM5 (rs2013208: PHDL=9x10
-12,
PCAD=7x10
-5) and CMTM6 (rs7640978: PLDL=1x10
-8, PCAD=4x10
-4).
We tested whether the LDL cholesterol-, total cholesterol- or triglyceride- increas-
ing allele or the HDL cholesterol- decreasing allele was associated with increased risk
of cardiovascular disease or related metabolic outcomes; the direction of effect of
each locus was categorized according to the primary association signal at the locus,
as in Tables 2.1, 2.2, 2.3, and 2.4. We observed association with increased CAD
risk (104/149; P=1x10-6), SBP (96/155; P=2.7x10-3) and WHR adjusted for BMI
(92/154; P=0.019). There were many instances where a single locus was associated
with many traits. These included variants near FTO, consistent with previous re-
ports (Freathy et al., 2008); near VEGFA (associated with triglyceride levels, CAD,
T2D, SBP and DBP); near SLC39A8 (associated with HDL cholesterol levels, BMI,
SBP and DBP); and near MIR581 (associated with HDL cholesterol levels, BMI,
T2D and DBP). In some cases, such as FTO, a strong association with BMI or
another phenotype generated weaker association signals for other metabolic traits
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(Freathy et al., 2008). In other cases, such as SORT1, a primary effect on lipid lev-
els might mediate secondary association with other traits, such as CAD (Musunuru
et al., 2010).
2.3.10 Association of lipid traits with CAD
Epidemiological studies consistently show that high total cholesterol and LDL
cholesterol levels are associated with increased risk of CAD, whereas high HDL
cholesterol levels are associated with reduced risk of CAD (Clarke et al., 2007).
In genetic studies, the connection between LDL cholesterol levels and CAD is clear,
whereas the results for HDL cholesterol levels are more equivocal (Willer et al., 2008;
Voight et al., 2012b; Frikke-Schmidt et al., 2008). In our data, trait-increasing al-
leles at the loci showing the strongest association with LDL cholesterol levels (31
loci), triglyceride levels (30 loci) or total cholesterol levels (38 loci) were associated
with increased risk of CAD (P=2x10-12, 2x10-16 and 0.006, respectively). Conversely,
trait-decreasing alleles at loci showing the strongest association with HDL cholesterol
levels (64 loci) were associated with increased CAD risk at P=0.02. When we fo-
cused on loci uniquely associated with LDL cholesterol levels (12 loci where P>0.05
for other lipids), triglyceride levels (6 loci) or HDL cholesterol levels (14 loci), only
the association with LDL cholesterol remained significant (P=0.03).
To better explore how associations with individual lipid levels were related to CAD
risk, we used linear regression to test whether association with lipid levels could pre-
dict impact on CAD risk. In this analysis, the effect on CAD of 149 lipid-associated
loci (CAD results were not available for 8 SNPs) was correlated with LDL cholesterol
(Pearson’s r=0.74; P=7x10-6) and triglyceride (Pearson’s r=0.46; P=0.02) effect
sizes but not with HDL cholesterol effect sizes (Pearson’s r=-9x10-4; P=0.99; (Fig-
ure 2.6). Because most variants affect multiple lipid fractions (Figure 2.3), dissecting
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the relationship between lipid level and CAD effects requires multivariate analysis.
In a companion manuscript in this issue, we use multivariate analysis and detailed
examination of triglyceride-associated loci to show that increased LDL cholesterol
and triglyceride levels but not HDL cholesterol levels appear to be causally related
to CAD risk (Do et al., 2013).
2.3.11 Evidence for additional loci not yet reaching genome-wide significance
To evaluate evidence for loci not yet reaching genome-wide significance, we com-
pared the directions of effect in GWAS and Metabochip analyses of non-overlapping
samples outside the 157 genome-wide significant loci. For independent variants
(r 2<0.1) with association P<0.1 in the GWAS-only analysis, a significant excess was
concordant in the direction of effect for HDL cholesterol levels (62.9% of 1,847 SNPs;
P<1x10-16), LDL cholesterol levels (58.6% of 1,730 SNPs; P<1x10-16), triglyceride
levels (59.1% of 1,783 SNPs; P<1x10-16) and total cholesterol levels (61.0% of 1,904
SNPs; P<1x10-16), suggesting that there are many additional loci to be discovered
in future studies.
2.4 Discussion
Molecular understanding of the genes and pathways that modify blood lipid levels
in humans will facilitate the design of new therapies for cardiovascular and metabolic
disease. This understanding can be gained from studies of model organisms, in vitro
experiments, bioinformatic analyses and human genetic studies. Here we demon-
strate association between blood lipid levels and 62 new loci, bringing the total
number of lipid-associated loci to 157 (Tables 2.1, 2.2, 2.3, 2.4, and Figure 2.3). All
but one of the loci identified here include protein-coding genes within 100 kb of the
SNP showing the strongest association. Whereas 38 of the 62 new loci include genes
35
whose role in the regulation of blood lipid levels is supported by literature review or
analysis of curated pathway databases, the remainder include only genes whose role
in such regulation has not been documented.
In total, there are 240 genes within 100 kb of 1 of our 62 new lipid-associated
loci-providing a daunting challenge for future functional studies. Prioritizing on the
basis of literature review, pathway analysis, regulation of mRNA expression levels
and protein-altering variants suggests that 70 genes in 44 of the 62 new loci might
be the focus of the first round of functional studies (summarized in Tables S2.3
and S2.4). Although we found significant overlap, different sources of prioritization
sometimes disagreed. This result suggests that truly understanding causality will be
very challenging. We include an interpreted digest of genes highlighted by our study
in Table S2.10. Clearly, a range of approaches will be needed to follow up these
findings. To illustrate possibilities, consider US Patent Application 20090036394
disclosing that, in the mouse, knockout of Gpr146 modifies blood lipid levels. Here
we show that variants near the human homolog of this gene, GPR146, are associated
with the levels of total cholesterol-providing an added incentive for studies of GPR146
inhibitors in humans. GPR146 encodes a G protein-coupled receptor, an attractive
pharmaceutical target, so it is tempting to speculate that, one day, pharmaceutical
inhibition of GPR146 may modify cholesterol levels and reduce risk of heart disease.
Each associated locus typically includes many strongly associated (and potentially
causal) variants. Our fine-mapping results illustrate how genetic analysis of large
samples and individuals of diverse ancestry can help focus the search for causal
variants. In our fine-mapping analysis of 65 lipid-associated loci, we were able to
separate the strongest signal in a region from the previous GWAS-identified signal
in 12 instances. In 3 of these 12 instances, fine-mapping was enabled by the analysis
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of a few thousand individuals of African or East Asian ancestry, whereas, in the
remaining instances, fine mapping was possible through the examination of nearly
100,000 individuals of European ancestry. A more detailed fine-mapping exercise,
including imputation of variants from emerging, very large reference panels, may
help refine the locations of additional signals.
Lipid-associated loci were strongly associated with CAD, T2D, BMI, SBP and
DBP. In univariate analyses, we found that effects on LDL cholesterol and triglyc-
eride levels all predicted association with CAD, but HDL cholesterol levels did not.
In a companion paper, more detailed multivariate investigation shows that our data
are consistent with the hypothesis that both LDL cholesterol and triglyceride levels
but not HDL cholesterol levels are causally related to CAD risk. HDL cholesterol,
LDL cholesterol and triglyceride levels summarize aggregate levels of different lipid
particles, each with potentially distinct consequences for CAD risk. We evaluated
the association of our loci with lipid subfractions in 2,900 individuals from the Fram-
ingham Heart Study (Figure S2.1 and Table S2.11) and with sphingolipids, which are
components of lipid membranes in cells, in 4,034 individuals from 5 samples of Eu-
ropean ancestry (Table S2.12). The results suggest that HDL cholesterol-associated
variants can have a markedly different impact on these subphenotypes. For example,
among HDL cholesterol-associated loci, variants near LIPC were strongly associ-
ated with plasmalogen levels (P<1x10-40), variants near ABCA1 were associated
with sphingomyelin levels (P<1x10-5), and variants near CETP, which show the
strongest association with HDL cholesterol levels overall, were associated with nei-
ther of these. Detailed genetic dissection of these subphenotypes in larger samples
could lead to functional groupings of HDL cholesterol-associated variants that rec-
oncile the results of genetic studies (which show no clear connection between HDL
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cholesterol-associated variants and CAD risk) and epidemiological studies (which
show clear association between plasma HDL cholesterol levels and CAD risk).
In summary, we report the largest genetic association study of blood lipid levels
yet conducted. The large number of loci identified, the many candidate genes they
contain and the diverse proteins they encode generate new leads and insights into
lipid biology. It is our hope that the next round of genetic studies will build on these
results, using new sequencing, genotyping and imputation technologies to examine
rare loss-of-function alleles and other variants of clear functional impact to accelerate




We collected summary statistics for Metabochip SNPs from 45 studies. Of these,
37 studies consisted primarily of individuals of European ancestry, including both
population-based studies and case-control studies of CAD and T2D. Another 8 stud-
ies consisted primarily of individuals with non-European ancestry, including 2 stud-
ies of individuals of South Asian descent, AIDHS/SDS (n=1,516) and PROMIS
(n=3,385); 2 studies of individuals of East Asian descent, CLHNS (n=1,771) and
TAI-CHI (n=7,044); and 5 studies of individuals of recent African ancestry, MRC/UVRI
GPC (n=1,687) from Uganda, SEY (n=426) from the Caribbean, and FBPP (n=1,614;
triglyceride results unavailable), GXE (n=397) and SPT (n=838) from the United




We genotyped 196,710 genetic variants prioritized on the basis of previous GWAS
for cardiovascular and metabolic phenotypes using the Illumina iSelect Metabochip
(Voight et al., 2012a) genotyping array. To design the Metabochip, we used our
previous GWAS of 100,000 individuals (Teslovich et al., 2010) to prioritize 5,023
SNPs for HDL cholesterol, 5,055 SNPs for LDL cholesterol, 5,056 SNPs for triglyc-
erides and 938 SNPs for total cholesterol. These independent SNPs represent most
loci with P<0.005 in our original GWAS for HDL cholesterol, LDL cholesterol and
triglycerides and with P<0.0005 for total cholesterol. An additional 28,923 SNPs
were selected for fine mapping of 65 previously identified lipid loci. The Metabochip
also included 50,459 SNPs prioritized on the basis of GWAS of non-lipid traits and
93,308 SNPs selected for fine mapping of loci associated with non-lipid traits (5 of
these loci were associated with blood lipids by the analyses described here).
2.5.3 Phenotypes
Blood lipid levels were typically measured after >8 hours of fasting. Individuals
known to be on lipid-lowering medication were excluded when possible. LDL choles-
terol levels were directly measured in ten studies (24% of total study individuals)
and were estimated using the Friedewald formula (Friedewald et al., 1972) in the
remaining studies. Trait residuals within each study cohort were adjusted for age,
age2 and sex and were then quantile normalized. Explicit adjustments for population
structure using principal-component (Price et al., 2006) or mixed-model approaches
(Kang et al., 2010) were carried out in 24 studies (35% of study individuals); all stud-
ies were adjusted using genomic control before meta-analysis (Devlin and Roeder,
1999). In studies ascertained on diabetes or cardiovascular disease status, cases and
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controls were analyzed separately. All meta-analyses were limited to a single ancestry
group (for example, European only).
2.5.4 Primary statistical analysis
Individual SNP association tests were performed using linear regression with the
inverse normal transformed trait values as the dependent variable and the expected
allele count for each individual as the independent variable. These analyses were per-
formed using PLINK (26 samples; 53% of the total number of individuals), SNPTEST
(4 samples; 20% of the total number of individuals), EMMAX (9 samples; 14% of
the total number of individuals), Merlin (4 samples; 9% of the total number of indi-
viduals), GENABEL (1 sample; 3% of the total number of individuals) and MMAP
(1 sample; 1% of the total number of individuals).
2.5.5 Meta-analysis
Meta-analysis was performed using the Stouffer method (Stouffer et al., 1949;
Willer et al., 2010) with weights proportional to the square root of the sample size
for each sample. To correct for inflated test statistics due to potential population
stratification, we first applied genomic control to each sample and then repeated
the procedure with initial meta-analysis results. For GWAS samples, we used all
available SNPs when estimating the median test statistic and inflation factor λ. For
Metabochip samples, we used a subset of SNPs (n=7,168) that had P -values of >0.50
for all lipid traits in the original GWAS, expecting that the majority of these would
not be associated with lipids and would behave as null variants in the Metabochip
samples. Signals were considered to be novel if they reached a P -value of <5x10-8
in the combined GWAS and Metabochip meta-analysis and were >1 Mb away from
the nearest previously described lipid-associated locus and other new loci. We used
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only European samples for the discovery of new genome-wide significant loci. Non-
European samples were used only for meta-analysis and examination of fine-mapping
analyses.
2.5.6 Quality control
To flag potentially erroneous analyses, we carried out a series of quality control
steps. Average standard errors for association statistics from each study were plotted
against study sample size to identify outlier studies. We inspected allele frequencies
to ensure all analyses used the same strand assignment of alleles. We evaluated
whether reported statistics and allelic effects were consistent with published findings
for known loci. Genomic control values for study-specific analyses were inspected,
and all were <1.20. Finally, within each study, we excluded variants for which the
minor allele was observed <7 times.
2.5.7 Proportion of trait variance explained
We estimated the increase in trait variance explained by new loci in the Framing-
ham cohort (n=7,132) using 3 models for each trait residual: (i) lead and secondary
SNPs from the previously published loci (Teslovich et al., 2010); (ii) previously pub-
lished lipid loci plus newly reported loci; and (iii) newly reported loci. We regressed
lipid residuals on these sets of SNPs using the lme kinship package in R.
2.5.8 Initial automated review of the published literature
An initial list of candidates within each locus was generated with Snipper and
then subjected to manual review. For each locus, Snipper first generates a list of
nearby genes and then checks for the co-occurrence of the corresponding gene names
and selected search terms (“cholesterol”, “lipids”, “HDL”, “LDL” or “triglycerides”)
in published literature and OMIM. We supplemented this approach with traditional
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literature searches using PubMed and Google.
2.5.9 Generating permuted sets of non-associated SNPs
To estimate the expected chance overlap between literature searches and our loci,
we generated lists of permuted SNPs. To generate these lists, we first identified
all non-associated lipid-related SNPs (P>0.10 for any of the four lipid traits) and
created bins on the basis of three statistics: MAF, distance to the nearest gene and
number of SNPs with r 2>0.8. For each index SNP, we identified 500 non-lipid-
associated SNPs that fell within the same 3 bins and randomly selected 1 SNP for
each permuted list.
2.5.10 Pathway analyses
To investigate whether lipid-associated variants overlapped previously annotated
pathways, we used gene set enrichment analysis (GSEA), as implemented in MA-
GENTA (Segre` et al., 2010) using the meta-analysis of all studies, including GWAS
and Metabochip SNPs. Briefly, MAGENTA first assigns SNPs to a given gene when
within 110 kb upstream or 40 kb downstream of transcript boundaries. The most
significant SNP P -value within this interval is then adjusted for confounders (gene
size, marker density and LD) to create a gene association score. When the same
SNP is assigned to multiple genes, only the gene with the lowest score is kept for
downstream analyses. Subsequently, MAGENTA attaches pathway terms to each
gene using several annotation resources, including GO, PANTHER, Ingenuity and
KEGG. Finally, the genes are ranked on the basis of their gene association scores, and
a modified GSEA test is used to test the null hypothesis that all gene score ranks
above a given rank cutoff are randomly distributed with regard to a given path-
way term (and compared to multiple randomly sampled gene sets of identical size).
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We evaluated enrichment using a rank cutoff of 5% of the total number of genes.
A minimum of 10,000 gene set permutations were performed, and up to 1,000,000
permutations were performed for GSEA P -values below 1x10-4.
We used the Disease Association Protein-Protein Link Evaluator package (DAP-
PLE) to examine evidence for protein-protein interaction networks connecting genes
across different lipid-related loci. This analysis included the 62 new loci as well as
the 95 previously known loci; we focus our discussion on pathways that included 1
or more genes from new loci.
2.5.11 Cis-expression quantitative trait locus analysis
To determine whether lipid-associated SNPs might act as cis regulators of nearby
genes, we examined association with the expression levels of 39,280 transcripts in 960
human liver samples, 741 human omental fat samples and 609 human subcutaneous
fat samples. Tissue samples were collected postmortem or during surgical resection
from donors; tissue collection, DNA and RNA isolation, expression profiling and
genotyping were performed as described (Keating et al., 2008). MACH was used to
obtain imputed genotypes for ∼2.6 million SNPs in HapMap release 22 for each of the
samples. We examined the correlation between each of the 62 new index SNPs and
all transcripts within 500 kb of the SNP position, performing association analyses as
previously described (Schadt et al., 2008).
2.5.12 Functional annotation of associated variants
We attempted to identify lipid-associated SNPs that fell in important regulatory
domains. We initially created a list of all potentially causal variants by selecting
index SNPs at loci identified in this study or in Teslovich et al. (2010). We then
selected any variant in strong LD (r 2>0.8 from the 1000 Genomes Project or HapMap
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data) with each index SNP. We compared the positions of the index SNPs and
their proxies to previously described functional marks (Ernst et al., 2011; ENCODE
Project Consortium, 2011). To assess the expected overlap with functional marks,
we created 100,000 permuted sets of non-associated SNPs (see Section 2.5.9) and
evaluated permuted SNP lists for overlap with functional domains. We estimated a
P -value for each functional domain as the proportion of permuted sets with an equal
or greater number of loci overlapping functional domains (for large P -values). For
small P -values, we used a normal approximation to the empirical overlap distribution
to estimate P -values.
2.5.13 Association with lipid subfractions
Lipoprotein fractions in samples from the Women’s Genome Health Study (WGHS)
(n=23,170) were measured using the LipoProtein-II assay (Liposcience), and Fram-
ingham Heart Study Offspring samples (n=2,900) were measured with the LipoProtein-
I assay (Liposcience) (Chasman et al., 2009). Additional information on subfraction
measurements can be found in Figures S2.1 and S2.2. Log transformations were
used for non-normalized traits. All models were adjusted for age, sex and principal
components. The genetic association analysis of WGHS used SNP genotypes im-
puted from the HapMap release 22 CEU (Utah residents of Northern and Western
European ancestry) reference panel using MACH. Of the 23,170 WGHS participants,
16,730 were fasting for 8 hours before blood draw (72.2%).
2.5.14 URLs
Summary results for our studies are available. We hope that they will facilitate
continued research into the genetics of blood lipid levels and, eventually, help iden-
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Table 2.1: New loci primarily associated with HDL cholesterol discovered from joint GWAS and
Metabochip meta-analysis






























rs12145743 1 156.70 HDL-C 0.34 G/T 0.020 181 2x10-8
ANGPTL1 rs4650994 1 178.52 HDL-C 0.49 G/A 0.021 187 7x10-9
CPS1 rs1047891 2 211.54 HDL-C 0.33 A/C -0.027 182 9x10-10
ATG7 rs2606736 3 11.40 HDL-C 0.39 C/T 0.025 129 5x10-8
SETD2 rs2290547 3 47.06 HDL-C 0.20 A/G -0.030 187 4x10-9
RBM5 rs2013208 3 50.13 HDL-C 0.50 T/C 0.025 170 9x10-12
STAB1 rs13326165 3 52.53 HDL-C 0.21 A/G 0.029 187 9x10-11
GSK3B rs6805251 3 119.56 HDL-C 0.39 T/C 0.020 186 1x10-8
C4orf52 rs10019888 4 26.06 HDL-C 0.18 G/A -0.027 187 5x10-8
FAM13A rs3822072 4 89.74 HDL-C 0.46 A/G -0.025 187 4x10-12
ADH5 rs2602836 4 100.01 HDL-C 0.44 A/G 0.019 187 5x10-8








DAGLB rs702485 7 6.45 HDL-C 0.45 G/A 0.024 187 6x10-12
SNX13 rs4142995 7 17.92 HDL-C 0.38 T/G -0.026 165 9x10-12
IKZF1 rs4917014 7 50.31 HDL-C 0.32 G/T 0.022 187 1x10-8
TMEM176A rs17173637 7 150.53 HDL-C 0.12 C/T -0.036 184 2x10-8
MARCH8-
ALOX5








OR4C46 rs11246602 11 51.51 HDL-C 0.15 C/T 0.034 176 2x10-10
KAT5 rs12801636 11 65.39 HDL-C 0.23 A/G 0.024 187 3x10-8
MOGAT2-
DGAT2
rs499974 11 75.46 HDL-C 0.19 A/C -0.026 187 1x10-8
ZBTB42-
AKT1
rs4983559 14 105.28 HDL-C 0.40 G/A 0.020 184 1x10-8








HAS1 rs17695224 19 52.32 HDL-C 0.26 A/G -0.029 185 2x10-13
a The secondary trait TG was most strongly associated with a different SNP, rs719726 (within 1 Mb of
rs1936800, r2=0.74)
b The secondary trait TG was most strongly associated with a different SNP, rs9930333 (within 1 Mb of
rs1121980, r2=0.99)
* Effect sizes are given with respect to the minor allele (A1) in SD units. For loci associated with two or
more traits at genome-wide significance, the trait corresponding to the strongest P-value is listed first.
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Table 2.2: New loci primarily associated with LDL cholesterol discovered from joint GWAS and
Metabochip meta-analysis
















rs267733 1 150.96 LDL-C 0.16 G/A -0.033 165 5x10-9
EHBP1 rs2710642 2 63.15 LDL-C 0.35 G/A -0.024 173 6x10-9
















FN1 rs1250229 2 216.30 LDL-C 0.27 T/C -0.024 173 3x10-8











































BRCA2 rs4942486 13 32.95 LDL-C 0.48 T/C 0.024 172 2x10-11
APOH-
PRXCA
rs1801689 17 64.21 LDL-C 0.04 C/A 0.103 111 1x10-11
SPTLC3 rs364585 20 12.96 LDL-C 0.38 A/G -0.025 172 4x10-10
SNX5 rs2328223 20 17.85 LDL-C 0.21 C/A 0.03 171 6x10-9
MTMR3 rs5763662 22 30.38 LDL-C 0.04 T/C 0.077 163 1x10-8
a The secondary trait TC was most strongly associated with a different SNP, rs17526895 (within 1 Mb of
rs10490626, r2=0.98)
b The secondary trait HDL-C was most strongly associated with a different SNP, rs13076253 (within 1 Mb
of rs17404153, r2=0.00)
c The secondary trait TG was most strongly associated with a different SNP rs4719841 (within 1 Mb of
rs4722551, r2=0.10)
* Effect sizes are given with respect to the minor allele (A1) in SD units. For loci associated with two or
more traits at genome-wide significance, the trait corresponding to the strongest P-value is listed first.
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Table 2.3: New loci primarily associated with total cholesterol discovered from joint GWAS and
Metabochip meta-analysis














ASAP3 rs1077514 1 23.77 TC 0.15 C/T -0.03 184 6x10-9
ABCB11 rs2287623 2 169.83 TC 0.41 G/A 0.027 184 4x10-12
FAM117B rs11694172 2 203.53 TC 0.25 G/A 0.028 187 2x10-9








PXK rs13315871 3 58.38 TC 0.10 A/G -0.036 187 4x10-8
KCNK17 rs2758886 6 39.25 TC 0.30 A/G 0.023 187 3x10-8
HBS1L rs9376090 6 135.41 TC 0.28 C/T -0.025 187 3x10-9
GPR146 rs1997243 7 1.08 TC 0.16 G/A 0.033 183 3x10-10










rs10904908 10 17.26 TC 0.43 G/A 0.025 187 3x10-11
PHLDB1 rs11603023 11 118.49 TC 0.42 T/C 0.022 187 1x10-8
PHC1-
A2ML1
rs4883201 12 9.08 TC 0.12 G/A -0.035 187 2x10-9








TOM1 rs138777 22 35.71 TC 0.36 A/G 0.021 185 5x10-8








a The secondary trait LDL-C was most strongly associated with a different SNP, rs4253776 (within 1 Mb
of rs4253772, r2=0.95)
* Effect sizes are given with respect to the minor allele (A1) in SD units. For loci associated with two or
more traits at genome-wide significance, the trait corresponding to the strongest P-value is listed first.
Table 2.4: New loci primarily associated with triglycerides discovered from joint GWAS and
Metabochip meta-analysis

































MET rs38855 7 116.36 TG 0.47 G/A -0.019 178 2x10-8
AKR1C4 rs1832007 10 5.25 TG 0.18 G/A -0.033 178 2x10-12
PDXDC1 rs3198697 16 15.13 TG 0.43 T/C -0.020 176 2x10-8
MPP3 rs8077889 17 41.88 TG 0.22 C/A 0.025 176 1x10-8
INSR rs7248104 19 7.22 TG 0.42 A/G -0.022 176 5x10-10








a The secondary traits TC and LDL-C were most strongly associated with a different SNP, rs6818397
(within 1 Mb of rs6831256, r2=0.18)
* Effect sizes are given with respect to the minor allele (A1) in SD units. For loci associated with two or





Literature	  search	  and	  downstream	  bioinformatics	  analyses	  for	  biological	  interpretation	  of	  novel	  loci	  
Discovery	  Set	  (P<5x10-­‐8,	  independent	  (r2<0.10),	  and	  >1Mb	  from	  any	  known	  lipid	  variant)	  
GWAS	  +	  Metabochip	  European-­‐speciMic	  
joint	  meta-­‐analysis	  
25	  GWAS	  discovery	  cohorts	  from	  Teslovich	  et	  al.	  2010	  phenotyped	  for	  LDL-­‐C,	  HDL-­‐C,	  TG,	  and	  TC;	  ~2.6	  million	  genotyped	  or	  imputed	  SNPs	  
GC	  correction	  
based	  on	  all	  
SNPs	  
23	  non-­‐overlapping	  GWAS	  	  
cohorts	  phenotyped	  for	  LDL-­‐C,	  HDL-­‐C,	  TG,	  and	  TC	  (n=94,595)	  
37	  Metabochip	  cohorts	  phenotyped	  for	  HDL-­‐C,	  LDL-­‐C,	  TG,	  and	  TC	  (n=93,982)	  
Metabochip	  Design	  
• 	  196,710	  SNPs	  based	  on	  GWAS	  
• 	  10,328	  replication	  SNPs	  
• 	  28,923	  Mine	  mapping	  SNPs	  for	  lipids	  
GC	  correction	  
based	  on	  all	  SNPs	  
GC	  correction	  based	  
on	  subset	  of	  SNPs	  
with	  P>0.50	  for	  all	  
lipid	  traits	  in	  
previous	  GWAS	  
GC	  correction	  
based	  on	  all	  
SNPs	  
meta-­‐analysis	  
Figure 2.1: GLGC metabochip meta-analysis study design.
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Figure 2.2: Quantile-quantile plots of trait-specific meta-analysis P -value distributions for (A)
LDL cholesterol, (B) HDL cholesterol, (C) Triglycerides, and (D) Total cholesterol. Points in blue
represent the P -value distribution after removing ±1 Mb of previously known lipid loci. There
is reduced inflation of P -values after removing ±1 Mb of all genome-wide significant loci (shown
in green). Genomic control lambda (λGC) values for all Metabochip SNPs were between 1.19
(triglyceride levels) and 1.28 (HDL cholesterol) and reflect the enrichment of associated SNPs in
the genotyping array. After removing SNPs within 1 Mb of previously reported associated variants,
the lambda values ranged from 1.00 (LDL cholesterol) to 1.10 (HDL cholesterol). After removing
SNPs in newly genome-wide significant loci, lambda values reached 1.00 for LDL cholesterol and
triglycerides, 1.05 for total cholesterol, and 1.07 for HDL cholesterol.
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                    HDL cholesterol (45): 
HDGF-PMVK, ANGPTL1,  
CPS1, ATG7, SETD2, RBM5,  
STAB1, GSK3B, C4orf52, FAM13A,  
ADH5, DAGLB, SNX13, IKZF1,  
TMEM176A, OR4C46, KAT5,  
         MOGAT2-DGAT2, ZBTB42-AKT1,  
     HAS1, PABPC4, ZNF648, COBLL1,  
  SLC39A8, ARL15, CITED2, KLF14,  
TRPS1, AMPD3, LRP4, PDE3A, MVK,  
SBNO1, SCARB1, LACTB,  
LCAT, CMIP, STARD3, ABCA8,  
PGS1, MC4R, ANGPTL4,  




MET, AKR1C4, PDXDC1, 
MPP3, INSR, MSL2L1, 
KLHL8, MAP3K1, TYW1B, 
PINX1, JMJD1C, CYP26A1, 
CAPN3, FRMD5, CTF1, 
PLA2G6 
Total cholesterol (18): 
ASAP3, ABCB11, FAM117B, 
PXK, KCNK17, HBS1L, GPR146, 
VIM-CUBN, PHLDB1, PHC1-
A2ML1, TOM1, EVI5, RAB3GAP1, 
RAF1, C6orf106, SPTY2D1, 
MAMSTR, ERGIC3 
           36 loci: 
INSIG2, LOC84931,  
CMTM6, CSNK1G3, SOX17,  
UGT1A1, VLDLR, DLG4,  
PPARA, PCSK9,  SORT1, APOB, 
ABCG5/8, MYLIP, HFE, LPA, 
PLEC1, ABO, ST3GAL4, OSBPL7, 
   LDLR, TOP1, LDLRAP1, MOSC1, 
     IRF2BP2, HMGCR, HLA, FRK, 
       DNAH11, NPC1L1,  
       CYP7A1, GPAM, 
        BRAP,HNF1A,  















LRPAP1,    
  TIMD4,    
   CILP2   
 
    1 locus:  
PIGV-NR0B2 








  2 loci: 
PPP1R3B, 
APOE 
2 loci: GCKR, NAT2 
 
1 locus: ACAD11  
 
LDL cholesterol (9): 
ANXA9-CERS2, EHBP1, 
BRCA2, FN1, APOH-PRXCA, 
SPTLC3, SNX5, MTMR3, 
NYNRIN 
Figure 2.3: Schematic summary of known lipid-associated loci reported from GWAS. The Venn
diagram illustrates overlap of genetic loci associated with different lipid traits. The number of loci
primarily associated with only one trait is reported in parentheses after the trait name and locus
names are listed below in italics. Loci that show association with two or more traits are shown in
the appropriate overlapping segments.
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Figure 2.4: Manhattan plots highlighting novel genome-wide significant lipid loci. Trait-specific loci
that reach genome-wide significance (P<5x10-8) from the European joint meta-analysis are shown
in red for (A) LDL cholesterol, (B) HDL cholesterol, (C) Triglycerides, and (D) Total cholesterol.
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Figure 2.5: Power to detect variants of different allele frequencies and effect sizes. Lipid effect sizes
of SNPs in the GWAS + Metabochip meta-analysis are shown in red (novel lipid loci) in comparison
to SNPs discovered by previous GWAS efforts (shown in blue and green). Dotted lines represent
power curves for the minimum effect sizes that could be identified for a given effect-allele frequency





















































































































































































Figure 2.6: Effect size correlations of lipid- and CAD- associated variants. Plots show coronary
artery disease (CAD) effect sizes against lipid effect sizes for SNPs showing primary association
with each lipid trait. All effect sizes were oriented to the lipid trait-increasing (LDL-C, TG, TC) or
trait-decreasing (HDL-C) allele. Diagonal lines represent regressions of predictor lipid effect sizes by
outcome CAD effect sizes for SNPs that show primary association with each trait including both
previously known and newly reported index SNPs. LDL-C effect sizes were strongly associated
with CAD effect sizes (Pearson r=0.74, P=7x10-6). The correlation between CAD effect size and
triglyceride effect size (Pearson r=0.46, P=0.02) was higher than that observed for HDL-C (Pearson
r=-9x10-4, P=0.99). Lipid effect sizes were transformed into SD units.
56
Figure S2.1: Association with lipid subfractions in Framingham Heart Study. Heatmaps show effect
sizes for association (P<0.10) with 23 lipid subfractions (Chasman et al., 2009) in Framingham
Heart Study (FHS) offspring with respect to the trait-decreasing allele of (A) HDL-C and trait-
increasing allele of (B) LDL-C, (C) TC, and (D) TG. Significant associations (P<0.05) of lipid-
associated SNPs with coronary artery disease (CAD) are annotated on the y-axis at both known
and novel genetic loci primarily associated with each trait. Dendrogram clustering of loci (y-axis)
and lipid subfraction phenotypes (x -axis) based on the effect sizes (beta) are also shown. Figure














































































































































































































































































*The beta for the strongest association observed, rs4420638 at the APOE locus and Lapoeser5apc
(beta=-0.62), is displayed as the minimum (-0.3) so that the color scale for the heatmap is more















































































































































































































































































































































































HDLLG Large particles of high density lipoproteinconcentrations determined by NMR, Exam 4
HDLSM Small particles of high density lipoproteinconcentrations determined by NMR, Exam 4
HDLSZ Weighted average for HDL size based on measurements of HDLP1 through HDLP6, Exam 4
Lapoeser5* ApoE concentrations in mg/dL using immunochemical technique by Servia, Exam 5
LCHYLO* Chylomicron particles size >220 nm (expressed as TG concentrations in mg/dl) and determined using NMR, Exam 4
LDLINT Medium particles of low density lipoprotein determined by NMR, Exam 4
LDLLG Large particles of low density lipoprotein determined by NMR, Exam 4
LDLSZ Weighted average for LDL size based on measurements of LDLP1 through LDLP6 determined by NMR, Exam 4
Lhdl25* HDL2 cholesterol subfractions after chemical precipitation
LIDLP* Intermediate density lipoprotein determined by NMR, Exam 4
LLDLSM Small particles of low density lipoprotein determined by NMR, Exam 4
Llpaconc Lipoprotein(a) concentration, Exam 3
LRLP-C* Remnant like particles measured using selective immunoseparation of lipoproteins using the Otsuka kit. Expressed as
cholesterol in mg/dL, Exam 4
LRLP-tg* Remnant like particles measured using selective immunoseparation of lipoproteins using the Otsuka kit. Expressed as
triglycerides in mg/dL, Exam 4
LVLDLINT* Medium particles of very low density lipoprotein determined by NMR, Exam 4
LVLDLLG* Large particles of very low density lipoprotein determined by NMR, Exam 4
VLDLSM Small particles of very low density lipoprotein determined by NMR, Exam 4
VLDLSZ Weighted average for VLDL size based on measurements of VLDLP1 through VLDLP6 determined by NMR, Exam 4
*Log transformed. All models were adjusted for age, sex and PCs. Low-, high-, intermediate- and very low-density lipoprotein particle
concentrations were measured by nuclear magnetic resonance (NMR).
61
Figure S2.2: Association with lipid subfractions in Women’s Genome Health Study. Heatmaps
show effect sizes for association (P<0.10) with 23 lipid subfractions (Chasman et al., 2009) in the
Women’s Genome Health Study (WGHS) with respect to the trait-decreasing allele of (A) HDL-C
and trait-increasing allele of (B) LDL-C, (C) TC, and (D) TG. Significant associations (P<0.05)
of lipid-associated SNPs with coronary artery disease (CAD) are annotated on the y-axis at both
known and novel genetic loci primarily associated with each trait. Dendrogram clustering of loci
(y-axis) and lipid subfraction phenotypes (x -axis) based on the effect sizes (beta) are also shown.








































































































































































































































































































































































































































































































































































llp: LDL large hmp: HDL medium vsp: VLDL small
lsp: LDL small ln.hmp: ln[HDL medium] vz: VLDL mean size
ln.lsp: ln[LDL small] hsp: HDL small ntg: TG by NMR
lz: LDL mean size hz: HDL mean size ln.ntg: ln[TG by NMR]
idlp: IDL total nhc: HDL-C by NMR TGGB: TG assay
ln.idlp: ln[IDL total] HDL: HDL-C assay ln.TGGB: ln[TG assay]
ldlp: LDL total vldlcp: VLDL total CHOL: Total Cholesterol
ln.ldlp: ln[LDL total] vlcp: VLDL large ln.vlcp: ln[VLDL large]
LDL: LDL-C assay hdlp: HDL total vmp: VLDL medium
hlp: HDL large ln.vmp: ln[VLDL medium]












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Chromatin States* Showing Excess Over-
lap with Lipid Loci
H1 embryonic stem cells (H1 ES)
2 Transcription Transition (HMM9) P=4x10-10
Transcription Elongation (HMM10) P=5x10-10
B-lymphoblastoid cells (GM12878) 0
Umbilical vein endothelial cells (HUVEC)
2 Transcription Transition (HMM9) P=2x10-7
Transcription Elongation (HMM10) P=6x10-7
Skeletal muscle myoblasts (HSMM) 1 Transcription Elongation (HMM10) P=6x10-8
Mammary epithelial cells (HMEC)
2 Transcription Transition (HMM9) P=6x10-11
Transcription Elongation (HMM10) P=2x10-9
Normal epidermal keratinocytes (NHEK)
2 Transcription Elongation (HMM10) P=2x10-8
Weak Transcription (HMM11) P=3x10-6
Normal lung fibroblasts (NHLF)
2 Transcription Elongation (HMM10) P=2x10-10
Transcription Transition (HMM9) P=8x10-8
Erythrocyticleukaemia cells (K562)
3 Weak Transcription (HMM11) P=1x10-11
Weak Enhancer (HMM7) P=2x10-10
Strong Enhancer (HMM5) P=4x10-8
Hepatocellular carcinoma cells (HepG2)
8 Strong Enhancer (HMM4) P=2x10-25
Weak Enhancer (HMM7) P=4x10-14
Weak Transcription (HMM11) P=2x10-11
Strong Enhancer (HMM5) P=5x10-11
Transcription Elongation (HMM10) P=3x10-10
Weak Enhancer (HMM6) P=1x10-7
Active Promoter (HMM1) P=4x10-7
Weak Promoter (HMM2) P=7x10-7
*Chromatin states were described previously (Ernst et al., 2011) based on hidden Markov models (HMM) of
histone methylation and acetylation marks from 9 cell types. SNPs in high linkage disequilibrium (r2>0.8
in 1000 Genomes Project European ancestry samples) with known or novel lipid loci were compared to
matched sets of HapMap SNPs (see Section 2.5.12).
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Table S2.8: Overlap with chromatin states, histone marks and transcription factor ChIP-Seq in
HepG2 Cells


































Overlap with Chromatin States from Ernst et al. (2011)* (13 tested)
Strong Enhancer (HMM4) 49 13.7 2x10-25 20 6.2 9x10-10
Weak Enhancer (HMM7) 60 26.9 4x10-14 25 11.9 3x10-5
Weak Transcription (HMM11) 99 62.1 2x10-11 41 26.4 9x10-5
Strong Enhancer (HMM5) 34 12.8 5x10-11 10 5.6 5x10-2
Transcription Elongation (HMM10) 65 35.4 3x10-10 26 15.4 1x10-3
Weak Enhancer (HMM6) 57 33.5 1x10-7 21 14.5 .013
Active Promoter (HMM1) 39 20.3 4x10-7 14 8.8 .039
Weak Promoter (HMM2) 45 24.8 7x10-7 15 10.6 .088
Transcription Transition (HMM9) 37 18.7 3x10-5 18 8.0 4x10-4
Overlap with Histone Marks (5 tested)
H3K9ac 97 47.3 3x10-22 37 20.1 6x10-8
H3K27ac 84 39.2 3x10-20 34 16.7 4x10-8
H3K4me3 88 47.9 2x10-15 34 20.1 7x10-5
H3K36me3 104 62.3 4x10-14 41 26.1 2x10-5
H3K4me2 111 74.3 8x10-12 44 31.1 7x10-5
Overlap with Open Chromatin (2 tested)
FAIRE 51 26.5 5x10-9 19 11.3 8x10-3
DNase hypersensitivity 33 18.3 2x10-4 12 8.1 .09
Overlap with Transcription Factor ChIP-Seq (11 tested)
HNF4 38 16.2 6x10-10 14 7.1 6x10-3
CEBP/β 40 20.4 1x10-5 16 9.1 .010
CTCF 55 37.6 4x10-4 21 16.2 .055
HSF1 9 2.6 1x10-3 4 1.1 .024
*Chromatin states were described previously (Ernst et al., 2011) based on hidden Markov models (HMM) of
histone methylation and acetylation marks from 9 cell types. Data for histone marks, open chromatin, and
transcription factor ChIP-seq were obtained from the ENCODE Project (ENCODE Project Consortium,
2011). SNPs in high linkage disequilibrium (r2>0.8 in 1000 Genomes Project European ancestry samples)
with known or novel lipid loci were compared to matched sets of HapMap SNPs (see Section 2.5.12). This
table lists only regulatory elements that exhibited a significant excess overlap (P<1x10-3 to account for 31















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table S2.10: Candidate genes at novel loci
ABCB11 (ATP-binding cassette, sub-family B, member 11) is involved in the ATP-dependent
secretion of bile salts (MIM 603201). Hepatic overexpression of Abcb11 in mice increased absorption
of cholesterol and promoted diet-induced obesity and hypercholesterolemia. G6PC2 encodes a glucose-
6-phosphatase catalytic subunit (MIM 608058). Variants at this locus have been implicated in liver
enzyme and fasting glucose levels.
ACAD11 (acyl-CoA dehydrogenase family, member 11) is involved in the β-oxidation of long-
chain fatty acids in muscle and heart (MIM 614288).
ADH5 (alcohol dehydrogenase 5 (class III), chi polypeptide) encodes a protein involved in
oxidation of long-chain primary alcohols and which catalyzes a step in the elimination of formaldehyde
(MIM 103710).
AKR1C4 (aldo-keto reductase family 1, member C4) encodes a protein that produces interme-
diates in bile acid biosynthesis and inactivates circulating steroid hormones (MIM 600451). AKR1C4 is
expressed exclusively in the liver and is transcriptionally regulated by LXRA.
ANGPTL1 (angiopoietin-like 1 gene) is a member of the angiopoietin family involved in angiogen-
esis, and widely expressed in highly vascularized tissues (MIM 603874).
ANXA9 (annexin A9) and CERS2 (ceramide synthase 2). ANXA9 is a calcium-dependent
phospholipid-binding protein (MIM 603319). CERS2 is involved in regulation of long acyl chain and
sphingolipid metabolism (MIM 606920).
APOH (Apolipoprotein H, also known as beta-2 glycoprotein I) and PRKCA (protein
kinase C, alpha). APOH is a glycoprotein that is involved in the activation of lipoprotein lipase and
which neutralizes negatively charged phospholipids (MIM 138700). PRKCA is activated by APOA1 and
diacylglycerol during cholesterol mobilization (MIM 176960).
ASAP3 (ArfGAP with SH3 domain, ankyrin repeat and PH domain 3) is a GTPase-activating
protein that promotes cell differentiation and migration and has been implicated in cancer cell invasion.
ATG7 (autophagy related 7) encodes a protein that is part of the autophagy machinery (MIM
608760). Dysfunction in autophagy canimpact systems related to intracellular energy utilization and
promote apoptotic cell death.
BRCA2 (breast cancer 2, early onset) is involved in maintenance of genome stability, specifically
the homologous recombination pathway for repair of double stranded DNA. Variants in the region can
increase risk of breast and other types of cancer (MIM 600185).
C4orf52 (chromosome 4 open reading frame 52). The nearest gene to the lead signal is an
uncharacterized gene with unknown function, and there are no other obvious candidate genes in the
locus.
CMTM6 (CKLF-like MARVEL). This gene belongs to the chemokine-like factor gene superfamily,
but the exact function of the encoded protein is unknown (MIM 607889).
CPS1 (carbamoyl-phosphate synthase 1, mitochondrial) encodes a mitochondrial enzyme that
catalyzes the first committed step of the urea cycle (MIM 608307). The lead variant encodes a threonine
to asparagine substitution previously associated with levels of homocysteine and fibrinogen.
CSNK1G3 (casein kinase 1, gamma 3) encodes a serine/threonine-protein kinase that is involved
in a number of cellular processes including DNA repair, cell division, nuclear localization and membrane
transport (MIM 604253).
DAGLB (diacylglycerol lipase, beta) catalyzes the hydrolysis of diacylglycerol (DAG) to 2-
arachidonoyl-glycerol, an abundant endocannabinoid (MIM 614016). Endocannabinoids function sig-
naling molecules, regulate axonal growth, and drive adult neurogenesis.
DLG4 (discs, large homolog 4) encodes a membrane-associated guanylate kinase and may function
at postsynaptic sites (MIM 602887). Nearby, DVL2 may also play a role in signal transduction (MIM
602151) and CTDNEP1 is involved in a phosphatase cascade regulating nuclear membrane biogene-
sis (MIM 610684). SLC2A4 is an insulin-regulated glucose transporter (MIM 138190). The variant
identified here was previously associated with alkaline phosphatase levels in plasma.
EHBP1 (EH domain binding protein 1). The mouse homologue of EHBP1 was down-regulated in
a transgenic Pcsk9 mouse model and up-regulated in a Pcsk9 knockout mouse.
FAM13A (family with sequence similarity 13, member A). FAM13A has a putative role in signal
transduction, and gene expression has been shown to be increased in response to hypoxia in cell lines
from several tissues (MIM 613299).
FAM117B (family with sequence similarity 117, member B) is an uncharacterized protein.
Nearby, BMPR2 encodes a bone morphogenetic protein receptor (MIM 600799). Defects in BMPR2
cause primary pulmonary hypertension.
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FN1 (fibronectin 1) is a glycoprotein involved in cell adhesion and migration processes including em-
bryogenesis, wound healing, blood coagulation, host defense, and metastasis (MIM 135600). Fibronectin
is one of the first extracellular matrix proteins deposited at atherosclerosis-prone sites, and is central in
the formation of atherosclerotic lesions.
FTO (fat mass and obesity associated) contributes to the regulation of the global metabolic rate,
energy expenditure and energy homeostasis (MIM 610966). Variants in this gene have been repeatedly
associated with obesity-related phenotypes, and it may act through hypothalamic regulation of food
intake.
GPR146 (G protein-coupled receptor 146) is an orphan G protein-coupled receptor. While no
ligand has yet been identified, knockout mice exhibit reduced cholesterol levels (U. S. Patent Filing
20090036394). The adjacent gene, GPER encodes the intracellular G protein-coupled estrogen receptor
1 (MIM 601805).
GSK3B (glycogen synthase kinase 3 beta) encodes a kinase involved in energy metabolism, neu-
ronal cell development, and body pattern formation (MIM 605004). In mice, Gsk3b activity regulates
pancreatic islet beta cell growth64. Nearby, NR1I2 encodes a nuclear receptor that can form a het-
erodimer with retinoic acid receptor RXR and involved with homeostasis of numerous metabolites,
including lipids (MIM 603065).
HAS1 (hyaluronan synthase 1) is one of three isozymes that synthesize hyaluronic acid, produced
during wound healing and tissue repair to provide a framework for growth of blood vessels and fibroblasts
(MIM 601463). The nearest gene, FPR3 (formyl peptide receptor 3) is involved in host defense and
inflammation (MIM 136539).
HBS1L (HBS1-like, S. cerevisiae) encodes a member of the GTP-binding elongation factor fam-
ily (MIM 612450). Variants at this locus regulate persistence of fetal hemoglobinin adults and other
haematological traits.
HDGF (hepatoma derived growth factor) and PMVK (phosphomevalonate kinase). HDGF
is a growth factor that may be involved in cell proliferation and differentiation (MIM 600339). PMVK
catalyzes the fifth reaction of the cholesterol biosynthetic pathway (MIM 607622). Nearby, CRABP2
(cellular retinoic acid binding protein 2) encodes a cytosol-to-nuclear shuttling protein involved in the
retinoid signaling pathway (MIM 180231).
IKZF1 (IKAROS family zinc finger 1) is a transcription factor that regulates the low-density
lipoprotein receptor in certain cell types.
INSIG2 (insulin induced gene 2). INSIG2 influences cholesterol metabolism, lipogenesis, and
glucose homeostasis in diverse tissues (MIM 608660).
INSR (insulin receptor) is a transmembrane tyrosine kinase receptor that binds insulin and stimulates
glucose uptake (MIM 147670). The receptor activates several downstream pathways.
LOC84931 (uncharacterized gene). The nearest gene to the lead signal is an uncharacterized gene
with unknown function, and there are no obvious candidate genes in the region.
LRPAP1 (low density lipoprotein receptor-related protein associated protein 1) encodes a
chaperone for the lipoprotein receptorrelated proteins (MIM 104225). Lrpap1 knockout mice exhibit
impaired export of LRP2 and VLDL receptors from the endoplasmic reticulum.
KAT5 (K(lysine) acetyltransferase 5). KAT5 is a positive regulator of PPARG transcription
involved in adipogenesis.
KCNK17 (potassium channel, subfamily K, member 17) passes outward current under physio-
logical potassium concentrations (MIM 607370). Variants 50 kb away at KCNK16 have been implicated
in type 2 diabetes.
MARCH8 (membrane-associated ring finger (C3HC4) 8, E3 ubiquitin protein ligase) and
ALOX5 (arachidonate 5-lipoxygenase). MARCH8 induces the internalization of several membrane
glycoproteins (MIM 613335). ALOX5 is a lipid metabolism enzyme that catalyzes the conversion of
arachidonic acid to leukotrienes, inflammatory mediators implicated in atherosclerosis and several cancers
(MIM 152390).
MET (met proto-oncogene (hepatocyte growth factor receptor)) encodes a receptor tyrosine
kinase that regulates hepatocyte cell proliferation, migration and survival (MIM 164860).
MIR148A (microRNA 148a). MicroRNAs are short non-coding RNAs involved in post-
transcriptional regulation of gene expression. miR-148a has been implicated in several cancers (MIM
613786).
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MOGAT2 (monoacylglycerol O-acyltransferase 2) and DGAT2 (diacylglycerol O-
acyltransferase 2). MOGAT2 plays a central role in absorption of dietary fat in the small intestine76.
DGAT2 encodes one of two enzymes that catalyze the final reaction in the synthesis of triglycerides, in
which diacylglycerol is covalently bound to long chain fatty acyl-CoA (MIM 606983).
MPP3 (membrane protein, palmitoylated 3) is a membrane-associated guanylate kinase that
regulates trafficking and processing of cell-cell adhesion molecule nectin-1/alpha (MIM 601114).
MTMR3 (myotubularin related protein 3) encodes a phosphatase that binds to phosphoinositide
lipids (MIM 603558).
OR4C46 (olfactory receptor, family 4, subfamily C, member 46). This signal is located in
a cluster of G-protein-coupled olfactory receptors, including OR5W2, OR5D13, and OR5AS1 (MIM
614273).
PDXDC1 (pyridoxal-dependent decarboxylase domain containing 1). Little is known about
this decarboxylase (MIM 614244). Variants at this locus have been shown previously to be associated
with circulating sphingolipid levels. About 300 kb away, PLA2G10 encodes a protein that releases
arachidonic acid from cell membrane phospholipids (MIM 603603).
PEPD (peptidase D) encodes an enzyme that hydrolyzes peptides with C-terminal proline or hydrox-
yproline residues and helps recycle proline (MIM 613230). Also at this locus are the genes encoding tran-
scription factors CCAAT/enhancer binding protein alpha and gamma (CEBPA (MIM 116897), CEBPG
(MIM 138972)), involved in adipogenesis. Variants in this locus are associated with adiponectin levels
and type 2 diabetes in East Asians.
PHC1 (polyhomeotic homolog 1) and A2ML1 (alpha-2-macroglobulin-like 1) is required to
maintain the transcriptionally repressed state of many genes (MIM 602978). A2ML1 is an inhibitor for
several proteases and binds to low density lipoprotein receptor-related protein 1 (MIM 610627).
PHLDB1 (pleckstrin homology-like domain, family B, member 1). PHLDB1 is an insulin-
responsive protein that enhances Akt activation, and PHLDB1 expression is increased during adipocyte
differentiation (MIM 612834).
PIGV (phosphatidylinositol glycan anchor biosynthesis, class V) and NR0B2 (nuclear
receptor subfamily 0, group B, member 2). PIGV is a mannosyltransferase that plays a role in
multiple cellular processes, including protein sorting and signal transduction (MIM 610274). NR0B2 is a
transcriptional regulator involved in cholesterol, bile acid, and fatty acid metabolism and glucose-energy
homeostasis.
PPARA (peroxisome proliferator activated receptor alpha) encodes a nuclear transcription
factor that regulates fatty acid synthesis, and oxidation and gluconeogenesis (MIM 170998). PPARA
regulates the expression of lipoprotein receptors and cholesterol transporters involved in the reverse
cholesterol transport pathway.
PXK (PX domain containing serine/threonine kinase) plays a critical role in epidermal growth
factor receptor trafficking by modulating ubiquitination of the receptor (MIM 611450).
RBM5 (RNA binding motif protein 5) is an hypothetical tumour suppressor gene encoding a nu-
clear RNA binding protein involved in the induction of cell cycle arrest and apoptosis (MIM 606884).
Nearby, MST1R encodes macrophage stimulating 1 receptor and is involved in host defense (MIM
600168).
RSPO3 (R-spondin 3). RSPO3 encodes a protein that regulates beta-catenin signaling, promotes
angiogenesis and vascular development (MIM 610574). In mouse, Rspo3 is required for Vegf expression
and endothelial cell proliferation. Variants in this locus are associated with waist-hip ratio, bone mineral
density and renal traits.
SETD2 (SET domain containing 2) encodes a histone methyltransferase specific for lysine-36
of histone H3, a mark associated with active chromatin (MIM 612778). Nearby, NBEAL2 encodes
neurobeachin-like 2, which may play a role in megakaryocyte alpha-granule biogenesis (MIM 614169).
SNX5 (sorting nexin 5) encodes a protein that binds to phosphatidylinositol 4,5-bisphosphate and is
involved in intracellular transport of cargo receptors from endosomes to the trans-Golgi network (MIM
605937).
SNX13 (sorting nexin 13). This gene belongs to the sorting nexin (SNX) family and the regulator
of G protein signaling (RGS) family (MIM 606589). It may be involved in several stages of intracellular
trafficking.
SOX17 (SRY (sex determining region Y)-box 17) encodes a transcription regulator that plays a
key role in the regulation of embryonic development and is required for normal looping of the embryonic
heart tube (MIM 610928).
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SPTLC3 (serine palmitoyltransferase, long chain base subunit 3). SPTLC3 catalyzes the rate-
limiting step of the de novo synthesis of sphingolipids (MIM 611120). Variants at this locus are associated
with circulating sphingolipid levels.
STAB1 (stabilin 1) encodes a large, transmembrane receptor involved in angiogenesis, lymphocyte
homing, cell adhesion, and receptor scavenging (MIM 608560). STAB1 mediates endocytosis of various
ligands, including low-density lipoprotein. Variants at this locus have been associated with waist-hip
ratio.
TMEM176A (transmembrane protein 176A) is a transmembrane protein (MIM 610334).
TOM1 (target of myb1). TOM1 shares its N-terminal domain in common with proteins associated
with vesicular trafficking at the endosomes (MIM 604700). Nearby, HMOX1 encodes an essential enzyme
in heme catabolism (MIM 141250). Hmox1 knockout mice have low plasma triglycerides and altered
composition of HDL.
UGT1A1 (UDP glucuronosyltransferase 1 family, polypeptide A1). This complex locus en-
codes several glycosyltransferases that transform small lipophilic molecules, such as steroids, bilirubin,
hormones, and drugs, into water-soluble excretable metabolites (MIM 191740). Variants at this locus
are associated with serum bilirubin levels.
VEGFA (vascular endothelial growth factor A) encodes a growth factor active in angiogenesis
and endothelial cell growth, promoting cell migration, and inhibiting apoptosis (MIM 192240). Variants
in this locus are associated with waist-hip ratio.
VIM (vimentin) and CUBN (cubilin, intrinsic factor-cobalamin receptor). VIM is an in-
termediate filament that controls the transport of LDL-derived cholesterol from a lysosome to the site
of esterification (MIM 193060). CUBN is a receptor for high-density lipoproteins/apolipoprotein A-I,
intrinsic factor-vitamin B12, and albumin (MIM 602997).
VLDLR (very low density lipoprotein receptor) binds VLDL and other lipoproteins and transports
them into cells (MIM 192977). VLDLR is expressed on the capillary endothelium of skeletal muscle,
heart, and adipose tissue.
ZBTB42 (zinc finger and BTB domain containing 42) and AKT1 (v-akt murine thymoma
viral oncogene homolog 1). ZBTB42 is a DNA-binding transcriptional repressor (MIM 613915).
AKT1 is a serine-threonine protein kinase that is activated by platelet-derived growth factor (MIM
164730). The Akt signaling pathway controls multiple cellular functions in the cardiovascular system,

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































GREGOR: evaluating global enrichment of trait-associated
variants in epigenomic features using a systematic,
data-driven approach
3.1 Abstract
The majority of variation identified by genome wide association studies falls in
non-coding genomic regions and is hypothesized to impact regulatory elements that
modulate gene expression. Here we present a statistically rigorous software tool
GREGOR (Genomic Regulatory Elements and Gwas Overlap algoRithm) for eval-
uating enrichment of any set of genetic variants with any set of regulatory features.
Using variants from five phenotypes, we describe a data-driven approach to deter-
mine the tissue and cell types most relevant to a trait of interest and to identify
the subset of regulatory features likely impacted by these variants. Last, we ex-
perimentally evaluate six predicted functional variants at six lipid-associated loci
and demonstrate significant evidence for allele-specific impact on expression levels.
GREGOR systematically evaluates enrichment of genetic variation with the vast col-
lection of regulatory data available to explore novel biological mechanisms of disease
and guide us toward the functional variant at trait-associated loci.
GREGOR, including source code, documentation, examples, and executables, is





The list of common genetic variants associated with complex disease continues to
grow as a result of increasingly powered genome wide association studies (GWAS)
(Welter et al., 2014). A large proportion of the associated variants are non-coding
and it has proven difficult to identify the functional variant at loci with many vari-
ants in tight linkage disequilibrium (LD). In addition, these loci often account for
only a small percentage of the trait heritability which makes any minor alteration of
transcript levels difficult to detect. Although eQTLs (expression quantitative trait
loci) in relevant tissues can highlight loci where variants likely impact transcription
of nearby genes, fine-mapping of the causal variant is plagued by the same LD pat-
terns that impact disease association studies. Common variation located outside of
protein-coding regions modulates regulatory elements in a cell-type specific manner
(Claussnitzer et al., 2014; Ernst et al., 2011; Kichaev et al., 2014; Lo et al., 2014;
Maurano et al., 2012; Parker et al., 2013; Pickrell, 2014; Thurman et al., 2012; Trynka
et al., 2013). Examining disease-associated variants in relation to genomic regions
of functional importance can give insight into the molecular mechanisms leading
to disease phenotypes, particularly when all associated variants are considered in
aggregate.
Our understanding of the location of regulatory elements in the genome has ex-
panded with the advent of chromatin immunoprecipitation followed by high-throughput
DNA sequencing (ChIP-Seq) technology and the Encyclopedia of DNA Elements
(ENCODE) Project (ENCODE Project Consortium, 2012). However, it is challeng-
ing to untangle meaningful biological understanding in a systematic manner, given
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the diverse set of data available from hundreds of cell types and tissues. With the
notion that non-coding genetic variation plays a role in transcriptional regulation
via regulatory epigenomic features, we can harness these data to gain knowledge of
important biological mechanisms. For example, genetic variation that impacts local
chromatin or methylation states and DNA accessibility can impact transcription in
a given cell. In a majority of associated genomic regions, the SNP (single nucleotide
polymorphism) supported by ENCODE data is a SNP in strong LD with the top
reported GWAS SNP (Schaub et al., 2012). Systematic chromatin profiling has re-
vealed that variants linked with the GWAS index variant, defined here as the most
strongly associated variant, are often positioned within enhancer elements active in
relevant cell types (Ernst et al., 2011). Furthermore, the overlap of particular histone
methylation marks with trait associated variants is cell type-specific, suggesting that
gene regulation is influenced by trait alleles in a cell type-specific manner (Trynka
et al., 2013). Previous work has used chromatin profiles and other ChIP-seq exper-
imental data to investigate GWAS variation and predict the impact of candidate
variants in particular genomic regions (Boyle et al., 2012; Claussnitzer et al., 2014;
Kichaev et al., 2014; Lo et al., 2014; Maurano et al., 2012; Pickrell, 2014; Thurman
et al., 2012; Ward and Kellis, 2012). However, these methods often do not consider
an appropriate control set for evaluating enrichment and do not always carefully
evaluate the most relevant tissues or cell types for enrichment of trait-specific varia-
tion. Identifying causal variants and mechanisms at GWAS loci remains a universal
scientific challenge.
With this motivation, we developed a statistically rigorous approach to quantify
enrichment of trait-associated variants in experimentally annotated functional ele-
ments such as open chromatin states, histone marks and protein-binding sites in
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relevant cell types to develop a clearer understanding of the underlying regulatory
mechanisms. We apply an algorithm and systematic scientific method for prioritizing
functional candidate variants at genome-wide significant trait-associated loci. Our
aims are threefold:
(i) elucidate the important tissue/cell types in which genetic variation impacts tran-
scription for a particular trait,
(ii) narrow our focus of the regulatory features underlying transcription disrupted
by trait-associated variants, and
(iii) use positional overlap with selected regulatory domains to identify potential
functional candidates at trait-associated loci.
To address these aims, we evaluate genetic variation identified by GWAS for five
metabolic phenotypes: blood pressure (International Consortium for Blood Pressure
Genome-Wide Association Studies et al., 2011), (C. Newton-Cheh and P. Munroe,
unpublished data), body mass index (Locke et al., 2015), coronary artery disease
(Coronary Artery Disease (C4D) Genetics Consortium, 2011; Schunkert et al., 2011),
lipids (Global Lipids Genetics Consortium et al., 2013) and type 2 diabetes (Morris
et al., 2012). We present GREGOR (Genomic Regulatory Elements and Gwas
Overlap algoRithm), an open source tool for evaluating enrichment as a method
to query the vast array of ENCODE data for the design of functional experiments,
enabling scientists with non-computational backgrounds to prioritize variants and
loci for functional follow-up (Figure 3.1).
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3.3 Methods
We hypothesize that the index variant reported by GWAS is not necessarily the
causal variant, owing to LD at associated regions. To account for this, we first create
a list of all potential causal variants by selecting variants in strong LD (r 2>0.7)
with trait-associated index SNPs in whole genome sequenced samples: the 1000
Genomes Phase 1 version 2 European Panel (1000 Genomes Project Consortium
et al., 2010). Reference data from non-European populations from the 1000 Genomes
Project are also available with GREGOR for selection of LD proxies. Although
many indicators of regulatory potential exist for non-coding regions, we select DNase
hypersensitive sites (DHSs) as a general marker of functional importance to address
our first scientific question: which cell type shows strongest enrichment of trait-
associated loci? We gather data from the ENCODE Project and when experimental
replicates are available, we calculate the union of DHSs derived from the same tissue
(Table S3.1). We then examine overlap of these potential causal SNPs with DHSs
from various different tissue categories. By the same approach, we later evaluate
the position of the index SNPs and their LD proxies relative to histone methylation
marks and ChIP-seq transcription factor binding sites (TFBS) , as well as previously
defined functional chromatin states.
We calculate the total number of trait-associated loci at which either the index
SNP or at least one of its LD proxies overlaps with a regulatory region across the
genome. In order to evaluate the significance of this observed overlap at each individ-
ual regulatory feature, we estimate the probability of the observed overlap of GWAS
SNPs relative to expectation using a set of matched control variants. For each GWAS
index SNP, we identify a set of 500 control SNPs randomly selected from across the
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genome that match the index SNP for: (i) number of variants in LD, (ii) minor allele
frequency (±1%) and (iii) distance to the nearest gene. When two or more GWAS
index SNPs match each other following the three criteria above, they share a set
of control SNPs. We consider that the number of index SNPs within its matched
control set of SNPs that overlaps a given feature follows a binomial distribution with
two parameters: (i) the number of GWAS index SNPs present in the control set (1 or
greater), and (ii) the proportion of SNPs within the control set or their LD proxies
that physically overlaps a feature. Considering the number of index SNPs that over-
laps with a feature, we compute the sum of independent binomial random variables.
Then for each regulatory feature, we calculate the fold-enrichment over expectation
and an enrichment P -value that represents the probability that the overlap of control
SNPs represented as a cumulative probability distribution is greater than or equal to
the observed overlap that we see from GWAS index SNPs (Figure S3.1, Table 3.1).
We evaluated the performance of our method using a range of parameters includ-
ing different numbers of variants in LD in the matched control sets, and matched
control set size (Figure S3.2). The magnitude of enrichment is generally consis-
tent across ranges of these parameters, and the subsequent results use r 2=0.7 with
matched control set size of > 500. P -values generated based on randomly permuted
sets of non-associated matched control SNPs are highly concordant with estimated
P -values (Section 3.7.4, Figure S3.3).
We attempted to evaluate the type I error rate of our enrichment method. We
tested enrichment of 50 sets of randomly selected SNPs in DHSs of different tissues.
SNP sets were matched with lipid-associated SNPs on 3 properties: number of LD
proxies, minor allele frequency and distance to the nearest gene. A QQ plot reveals
P -values that closely follow the null uniform distribution, whereas the P -value dis-
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tribution for lipid-associated variants sharply deviates from the null (Figure 3.2a).
Additionally, we investigated type I error by first partitioning DHSs of each tissue
into genic landmark categories (Parker et al., 2013) and then randomly shuffling
within each category. After re-combining the DHS categories for each tissue, we
evaluated enrichment of the lipid-associated variants and again compared the results
to the original P -value distribution (Figure 3.2b).
3.4 Results
3.4.1 Prioritizing tissue types for five phenotypes using DNase hypersensitivity sites
Our first objective is to use available epigenomic data to identify which tissues
are the most biologically relevant to the trait-specific genetic variation identified by
GWAS. We evaluated enrichment of independent GWAS loci for five related phe-
notypes: 99 blood pressure loci (BP; 2.2% trait variance explained), 97 body mass
index loci (BMI; 2.7% trait variance explained) (Locke et al., 2015), 36 coronary
artery disease loci (CAD; 10% trait variance explained) (Schunkert et al., 2011), 157
lipid loci (high- and low- density lipoprotein cholesterol, total cholesterol and triglyc-
erides; 10-12% trait variance explained) (Global Lipids Genetics Consortium et al.,
2013) and 65 type 2 diabetes loci (T2D; 10.7% trait variance explained) (Morris
et al., 2012). DHSs are open regions of DNA accessible to protein binding, and are
important in the transcriptional activity within a given cell. ENCODE has exper-
imentally identified DHSs using DNase-seq in hundreds of cell types. We evaluate
enrichment of GWAS loci in the union DHSs of cell types derived from the same
tissue (Table S3.1). By testing five sets of trait-associated SNPs in DHSs of 41 tissue
types, we set a Bonferroni corrected threshold for significance at P<2.4x10-4.
GWAS loci were significantly enriched in DHSs of tissues that are remarkably
consistent with our biological understanding of the trait (Figure 3.3). For example,
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BP-associated variants are highly enriched in DHSs in cell types derived from blood
vessel (P=1.2x10-9; fold enrichment 1.5) and heart (P=5.3x10-8; fold enrichment
1.6); CAD-associated variants in DHSs from heart (P=2.3x10-5; fold enrichment 1.7)
and blood (P=5.6x10-5; fold enrichment 1.4); lipid-associated variants in DHSs from
liver (P=2.0x10-14; fold enrichment 1.6), monocytes (P=7.1x10-13; fold enrichment
1.9) and blood (P=4.7x10-11; fold enrichment 1.4); and BMI-associated variants in
DHSs in frontal cortex (P=8.8x10-5; fold enrichment 1.7). We also find enrichment
of BMI-associated variants in DHSs of human olfactory neurosphere-derived cells
from mucosal biopsies (P=4.2x10-5; fold enrichment 1.7), suggesting a plausible link
between olfaction and food intake. However, there are other cases in which we find
enrichment of trait-associated variants in unexpected tissue types. For example, al-
though we observe significant enrichment of T2D-associated variants in pancreatic
tissue as expected (P=1.0x10-4; fold enrichment 1.6), we see stronger evidence for en-
richment in heart tissue (P=1.4x10-6; fold enrichment 1.7) and embryonic stem cells
(P=2.5x10-6; fold enrichment 1.5). We used this knowledge to guide subsequent en-
richment analysis of other epigenomic features by focusing on the most significant cell
types to reduce the multiple testing burden in subsequent assessments of additional
regulatory features. This data-driven approach to reduction of a large set of poten-
tially relevant regulatory elements in a myriad of cell lines and tissues can be used
for phenotypes where little is known about the biology, and may also identify novel
tissues where these GWAS loci are actively transcribed. Alternatively, investigators
might bypass this step and instead use a priori biological knowledge to focus on a
specific tissue or cell type. One could also integrate the two approaches to choose
some empirically-selected cell types but up-weight biologically relevant cell types.
We additionally investigate whether enrichment is tissue type-specific. Given the
89
wealth of DHS data available, often in replicates and for multiple cell types from the
same tissue type, we hypothesize that each cell type has some level of missing data
and artifacts. To address this, we define consensus regions of open chromatin that are
commonly shared among at least 50% of all cell types within a single tissue group, and
re-evaluate enrichment of lipid-associated GWAS variants. We additionally compare
results for consensus thresholds (proportion of cell types required to show a DHS
at that genomic position) of 100%, 75%, 25% and the union of cell types derived
from the same tissue. We found that when we used stricter definitions to select
functional regions (e.g. 100% of cell types were required to share the DHS), we
typically observed higher fold enrichment, but less significant enrichment P -values
(Figure S3.4). Conversely, when we relaxed the criterion to allow DHSs observed
in only 25% of cell types, we typically observed stronger P -values but lower fold
enrichment. This is likely due to inclusion of more artefactual DHSs using the relaxed
definition, but exclusion of true DHSs under the strict definition. In subsequent
analyses, we used the most relaxed definition of regulatory elements by including any
element observed in at least one replicate or cell type within each tissue category.
We opted to be more inclusive to allow for the most complete identification of DHSs.
3.4.2 Prioritizing regulatory elements in selected tissues
Following prioritization of important tissue types for GWAS of a specific pheno-
type, we next selected specific regulatory elements that were enriched for GWAS
variants in cell types derived from relevant tissues, focusing solely on the tissues se-
lected in Section 3.4.1. We evaluated enrichment of trait-associated variants in chro-
matin states predicted from histone methylation marks and a learned multivariate
hidden Markov model (Ernst et al., 2011) (Figure 3.4). Confirming previous reports
(Maurano et al., 2012), we found significant enrichment of genetic variation in weak
90
and strong enhancer states for nearly all phenotypes tested. Trait-associated vari-
ants are most highly enriched in active promoters commonly marked by H3K4me2,
H3K4me3, acetylation, or H2A.Z. There is less striking enrichment in domains that
contain repressed genes such as H3K9me2, H3K9me3 or H3K27me3.
We further evaluated enrichment in TFBS and histone modifications identified by
ChIP-Seq. We investigated any Tier 1 or 2 ENCODE cell types available for relevant
tissues identified in Section 3.4.1, taking the union of experimental replicates when
available. For cell types HepG2, Monocytes CD14+ (RO01746), GM12878, K562
and CD20+ (RO01778), we find significant enrichment of lipid-associated variation
for key transcriptional machinery including RNA Polymerase II (P=6.2x10-24; fold
enrichment 2.0) and the ubiquitous transcription factor SP1 (P=1.510-15; fold en-
richment 3.0). In addition, lipid-associated variants are highly enriched in binding
sites of RCOR1 (P=1.8x10-16; fold enrichment 2.1), EP300 (P=1.2x10-14; fold enrich-
ment 2.0), JUND (P=2.2x10-14; fold enrichment 2.0) and H3K4me3 (P=1.4x10-13;
fold enrichment 2.1). We tested a total of 158 regulatory features, 75 of which reach
Bonferroni significance with P<3.2x10-4 (Table S3.2). We are particularly interested
in 15 known lipid gene regulators as well as 16 transcription factors and 4 histone
markers associated with lipid change in the literature. Of the 75 Bonferroni signifi-
cant regulatory features, 18 of these are among this a priori -defined lipid-related list
of 35 elements.
3.4.3 Prioritizing candidate functional variants using selected regulatory elements in
relevant tissues
As we gain knowledge about the transcriptional machinery that acts in concert
with trait-associated genetic variation, we can make more informed predictions about
potential functional variants at a single locus. We hypothesize that variants present
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within multiple regulatory domains are more likely to play a role in transcriptional
regulation within a cell. Subsequently, we can use this information in combination
with functional protein-coding information, transcript level annotation, and delete-
riousness scoring to prioritize loci and individual variants for functional follow-up.
We proceeded to prioritize potential functional variants in the 157 known lipid-
associated loci (Figure 3.5). With the assumption that a protein-coding variant
is likely the functional driver of transcription at a given locus, we excluded any
lipid-associated loci from follow-up consideration that contains at least one non-
synonymous variant in LD (r 2>0.7) with the GWAS index SNP. This resulted in
103 remaining loci for further evaluation. We next examined our results from Step
2 to focus on the selected transcription factors and histone marks, and prioritized
loci at which multiple transcription factors bind in blood, monocytes, or liver. In a
data-driven approach, we flagged variants that overlap with a subset of significantly
enriched regulatory domains as plausible functional candidate SNPs (n=23). We
evaluated overlap of GWAS variants at candidate loci in lipid gene regulators as
well as transcription factors and histone marks involved with lipid change in the
literature. Variants at a set of five of these loci that overlap with at least eight
(25%) lipid-related regulatory features were commonly found using both the data-
driven and biological-driven selection of regulatory features, including the known
functional variant rs12740374 at SORT1 (Musunuru et al., 2010). Many of these
candidate variants are also eQTLs in liver, omental fat or subcutaneous fat or had
at least one surrogate SNP in LD (r 2>0.7) with the eQTL SNP at that locus (eQTL
P<1x10-3) (Schadt et al., 2008). In addition to considering these various data, we
counted the number of variants at each locus and focused on loci with relatively few
numbers of variants to increase the likelihood of identifying the functional variant.
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Thus, we narrowed down the list of lipid loci that likely have a strong impact on
regulating transcription to guide us to promising candidates for functional follow-up.
After analyzing the overlap of non-coding variants with biological TFBS from
ChIP-seq and using our criteria of non-coding variants, eQTLs, and number of vari-
ants at a locus, we chose five loci and picked one SNP from each region that had
some evidence of being the functional variant due to overlap with the most reg-
ulatory regions for further study (FAM117B : rs11692610; ANGPTL8 : rs737337;
SPTLC3 : rs1321940; IRF2BP2 : rs526936; ADH5 : rs1800759) (Figure 3.6). At
each locus, we selected an additional variant with no predicted C/EBP binding site
overlapping as an internal control (FAM117B : rs11694172; ANGPTL8 : rs3810308;
SPTLC3 : rs364585; IRF2BP2 : rs514230; ADH5 : rs2602836). Variant rs12740374
from the SORT1 locus has previously been demonstrated to alter a C/EBP TFBS
(Musunuru et al., 2010), and thus was used as a positive control here (rs629301 as
the SORT1 locus internal control).
We next attempted to directly determine the allele-specific effects of the non-
coding SNP polymorphism on transcription factor binding at each of the six lipid
loci. We generated luciferase constructs containing ± 300-400 bp around each genetic
variant (generating the alternate allele with site-directed mutagenesis) and trans-
fected them into HepG2 cells over-expressing C/EBP-β. We normalized luciferase
activities to the pcDNA3.1-co-transfected groups (control construct with no C/EBP-
β DNA inserted), and found robust luciferase activity increase in the rs12740374-T
construct compared with rs12740374-G from the SORT1 locus (fold increase=1.8,
P=4x10-4), which was consistent with the previous report. Similarly, for the other
five loci examined, the single nucleotide changes in other predicted functional SNP
sites caused significant luciferase activity differences in response to C/EBP-β over-
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expression (P<0.05), indicating those non-coding variants may change transcription
factor binding activity in GWAS loci and possibly affect downstream gene expression
(Figure 3.7). After correction for 12 tests (2 SNPs at six loci), we still find signifi-
cant differences between the two alleles (P<0.05) at the candidate functional SNP for
five out of the six loci (SORT1 : rs12740374-T; ANGPTL8 : rs737337-C; FAM117B :
rs11692610-T; IRF2BP2 : rs526936-C; SPTLC3 : rs1321940-G). In contrast, the lu-
ciferase signal changes of the internal control SNP constructs were significant at
Bonferroni levels for only two of the six loci.
Our results are generally supported by post hoc annotations of predicted regula-
tory elements defined by RegulomeDB (Boyle et al., 2012). For example, the Regu-
lomeDB score of the GWAS HDL cholesterol-associated index SNP at the SPTLC3
locus (rs364585) is 5, indicating that there is TF binding or DNase peak epigenomic
data to support its functionality. In contrast, the RegulomeDB score of our pre-
dicted functional SNP at this locus (rs1321940) is 2a, indicating that it is likely to
affect binding based on evidence of TF binding, and the presence of a matched TF
motif, DNase footprint, and DNase peak. Among all 18 variants within r 2>0.7 of
the index SNP at this locus, only 2 SNPs have a score of 2b or better. We observe
similar trends for other loci at which we performed experimental follow-up (Fig-
ure 3.6). Counterintuitively, the known functional variant rs12740374 at the SORT1
locus has a RegulomeDB score of 2b, whereas the variant reported by GWAS in
that region, rs629301, has a higher score of 1f. This result emphasizes the need to
consider multiple sources of data when prioritizing functional candidates for experi-
mental follow-up. Although annotation of individual variants is useful in predicting
the potential impact of a single variant, GREGOR considers all trait-associated vari-
ants in aggregate to prioritize which functional elements and in which tissues they
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are most relevant for the trait being examined. An alternative is considering the
entirety of ENCODE data, much of which will represent irrelevant tissue types or
highly correlated data sets.
3.5 Discussion
We have developed a systematic approach for evaluating enrichment of trait-
associated variants in epigenomic features, allowing us to prioritize tissues, regulatory
elements, and potential functional variants that affect transcriptional regulation (Fig-
ure 3.1). Our method takes into account all potential causal variants at a locus due
to LD and estimates enrichment with particular regulatory features using matched
control variants. It is an unbiased approach that can be used to narrow the focus of
cell types and regulatory features that does not rely on a priori knowledge of biologi-
cal mechanisms. The resultant findings will guide us to a more global understanding
of the underlying epigenomic architecture leading to trait-specific variation.
We present here one reasonable approach for prioritizing the potential functional
variant at a locus. We attempted to select loci with the best chance of demonstrating
a functional variant for experimental follow-up. However, our approach is limited
to only one potential functional variant per locus and does not claim to definitively
identify the true or only functional variant at any locus. More comprehensive interro-
gation of variation within a locus will be required to fully understand the underlying
molecular mechanisms involved.
Different cell types and tissues are more easily accessible than others for sequenc-
ing. This approach will become even more impactful as we develop an increasingly
comprehensive and diverse interrogation of the epigenome to answer important bio-
logical questions about the regulatory role of non-coding variation. In all, this ap-
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proach will help guide our knowledge of the important mechanisms occurring outside
of protein-coding regions that underlie cell-type-specific transcriptional regulation.
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3.7 Supplementary Methods
3.7.1 Data acquisition and pre-processing
DNase-seq ENCODE data for all available cell types were downloaded in the pro-
cessed narrowPeak format. The local maxima of the tag density in broad, variable-
sized hotspot regions of chromatin accessibility were thresholded at FDR 1% with
peaks set to a fixed width of 150 bp. Individual cell types were further grouped into
41 broad tissue categories (http://genome.ucsc.edu/ENCODE/cellTypes.html) by
taking the union of DHSs for all related cell types and replicates (Table S3.1). We
also obtained a set of BED files in hg19 assembly from the Integrative Analysis
and original ENCODE analysis. These data include uniformly processed datasets
in 125 cell types generated by the “Open Chromatin” (Duke University) and Uni-
versity of Washington (UW) ENCODE groups. Data processed during the EN-
CODE Integrative Analysis were downloaded for available tissues. Otherwise, data
from the original ENCODE analysis were obtained. We examined the overlap of
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DHSs across different cell types, and found that as expected, cell types derived
from related tissues generally clustered together. In addition, we examined chro-
matin state segmentation by HMM generated from ENCODE/Broad in nine human
cell types, as well as transcription factor binding sites by ChIP-seq from the EN-
CODE Analysis Working Group (AWG) including ENCODE/HudsonAlpha (HAIB),
ENCODE/Stanford/Yale/Davis/Harvard (SYDH), ENCODE/Univ of Chicago, EN-
CODE/Open Chrom (UT Austin), and ENCODE/Univ of Washington (UW). No
dataset analyzed was under embargo.
3.7.2 Selecting matched control SNPs for GWAS index SNPs
For each GWAS locus, we selected a set of matched control SNPs based on 3
criteria: i) number of variants in LD (r 2>0.7; ± 8 variants), ii) minor allele frequency
(± 1%), and iii) distance to nearest gene (± 11,655 bp). To calculate the distance
to the nearest gene, we calculated the distance to the 5’ flanking gene (start and end
position) and to the 3’ flanking gene and then used the minimum of these 4 values.
If the SNP fell within the transcribed region of a gene, the distance was 0.
3.7.3 Estimating probability of observed and expected overlap between a regulatory
feature and GWAS locus
We estimated the probability that a set of GWAS loci overlap with a regulatory
feature more often than we expect by chance using the following method. We con-
sidered a GWAS locus as the GWAS index SNP or a SNP in LD with the index
SNP (r 2>0.7). For each regulatory feature, we counted the number of GWAS loci in
which we observed physical overlap with at least one experimentally defined genomic
region of the feature. The number of GWAS index SNPs in the ith matched control
set that demonstrates positional overlap with a given epigenomic feature, written
as si, follows a binomial distribution with parameters ni and pi. The parameter ni
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is equal to the number of index SNPs present in the ith control set. The second
parameter pi is calculated as the number of variants in the ith control set or their
LD proxies that overlaps with the feature, divided by the total number of variants in
the ith control set. If we assume there are r control sets in total, the number of index
SNPs from all control sets that falls in a single feature is the sum of independent





In most cases only one index variant is assigned to a matched control set, but there
are some exceptions where more than one index SNP could match on the same 3
properties. We estimate an enrichment P -value for any given s as P(S ≥ s). P is
the cumulative right tail probability based on the distribution of S and is calculated
using a saddlepoint approximation method (Eisinga et al., 2013).
3.7.4 Permutation testing to evaluate estimated P-values
We performed up to 100,000 permutations to evaluate our enrichment P -value
estimation method and found the results to be highly concordant for permutation P -
values less than 1x10-5 that could be estimated (Figure S3.3). To assess the expected
overlap with a regulatory domain, we generated 100,000 random permuted sets of
non-associated matched control SNPs based on the criteria described above. We
selected a control variant from the control pool for each locus and identified the
variants in LD, resulting in 100,000 control sets. We evaluated the random SNP
lists for overlap with each functional domain by averaging the number of SNPs that
fell within the experimentally annotated regions from each control set that had at
least one variant overlapping a regulatory element. This approach assumes that
only one variant located in a regulatory region at each locus is responsible for the
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association signal. We calculated an empirical P -value for each regulatory dataset
as the proportion of random sets with an equal or greater number of loci overlapping
the regulatory domain than the observed set of trait-associated variants. For small
P -values that could not be estimated (e.g. P<1x10-5 for 100,000 permutations),
we used a normal approximation of the empirical overlap distribution to estimate
P -values.
3.7.5 Luciferase expression constructs
To characterize the intergenic region around the candidate SNPs, 600-800 bp
fragments containing the SNPs from human chromosomes were cloned into the pGL4-
Promoter vector (Promega), in the 5’-to-3’ orientation (toward the GWAS candidate
gene), upstream of the firefly luciferase gene (Table S3.3). The QuikChange Site-
Directed Mutagenesis Kit (Stratagene) was used to alter single nucleotides at the
targeted SNP sites. All constructs were verified by DNA sequencing.
3.7.6 Luciferase expression assays
HepG2 cultured human hepatoma cells were transfected at roughly 50% conflu-
ence and maintained in DMEM with 10% FBS. The firefly luciferase constructs were
co-transfected with either the C/EBP-β expression plasmid (pcDNA3.1-C/EBP-β)
or empty pcDNA3.1 vector, together with the Renilla luciferase pRL-null Vector
(Promega) as internal control, using the Lipofectamine 2000 transfection reagent
(Invitrogen) in the ratio 0.25µg:0.25ug:25ng:2.5µl mixed with Opti-MEM I Reduced
Serum Medium (Invitrogen) for a 50µl mix used for each well of 24-well plates. Forty-
eight hours after transfection, firefly and Renilla luciferase activities were measured
using the Dual-Luciferase Reporter Assay System (Promega) according to the man-
ufacturers protocol, using untransfected cells to adjust for background activity.
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3.7.7 Data Access
GREGOR documentation and software download,
http://genome.sph.umich.edu/wiki/GREGOR; ENCODE Consortium,
http://genome.ucsc.edu/ENCODE/dataMatrix/encodeDataMatrixHuman.html;
Chromatin state segmentation by HMM from ENCODE/Broad in 9 human cell types,
http://genome.ucsc.edu/cgibin/hgFileUi?g=wgEncodeBroadHmm&db=hg19;
GWAS results for all traits and diseases including those studied here,
http://www.genome.gov/gwastudies/. Data used from the latest blood pressure
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Experimental Follow-up of Functional Candidates 
Evaluate allele-specific enhancer activity at a subset of loci 
Figure 3.1: GREGOR study design.
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A. Index SNP Permutations

















































































B. DHS Partition−Specific Shuffling
Figure 3.2: Type I error assessment of GREGOR algorithm performance. (A) The P -value distri-
bution of enrichment in DHSs is shown for 50 SNP proxy lists (pink) together with the enrichment
P -value distribution of the true lipid-associated variants (blue). Proxy lists were generated by
choosing SNPs that matched on i) number of LD proxies, ii) minor allele frequency, and iii) gene
proximity, but were otherwise randomly selected from across the genome. (B) DHSs were par-
titioned into mutually exclusive genic landmark categories based on GENCODE annotation (e.g.
3’UTR, 5’UTR, intron, coding exon, intergenic TSS distal and proximal) and randomly shuffled.
After re-combining the categories for each tissue, we evaluated enrichment of lipid-associated vari-
ants (pink) and compared with the P -value distribution in the original DHSs (blue). Abbreviations:



















































































































































































































































































































































Figure 3.4: Enrichment of trait-associated variants in predicted chromatin states. Matrix of fold
enrichment for five sets of GWAS variants (A. body mass index, B. blood pressure, C. coronary
artery disease, D. lipids, E. type 2 diabetes) with boxes colored by -log10 enrichment P -value. White
boxes indicate not significant after Bonferroni correction for 15 chromatin states and nine human
tissues (Ernst et al., 2011). Abbreviations: HMM, hidden Markov model; txn, transcription; lo, low





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































E. Type 2 Diabetes
2.7 4.6
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Lipid-­‐associated	  loci	  reported	  from	  GWAS	  (Willer	  et	  al.,	  2013)	  
(n=157)	  
Loci	  without	  any	  non-­‐synonymous	  SNPs	  in	  LD	  (r2	  >	  0.7)	  with	  index	  SNP	  
(n=103)	  
Loci	  containing	  a	  SNP	  that	  overlaps	  with	  at	  least	  10%	  of	  
significantly	  enriched	  TFBSs	  or	  histone	  marks	  (n=23)	  
Loci	  with	  less	  than	  32	  SNPs	  (n=14)	  
Loci	  that	  contain	  an	  eQTL	  and/or	  a	  SNP	  that	  overlaps	  with	  at	  
least	  25%	  of	  significantly	  enriched	  lipid-­‐related	  features	  (n=11)	  
PosiSve	  control	  SORT1	  and	  randomly	  selected	  set	  of	  5	  
addiSonal	  loci:	  
ADH5,	  SPTLC3,	  ANGPTL8,	  FAM117B,	  IRF2BP2	  
Figure 3.5: Prioritization of lipid-associated loci for functional follow-up.
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Figure 3.6: Physical overlap of variants at six lipid loci with regulatory features. SNPs within r2 >
0.7 of the GWAS index SNP at each locus are shown with ChIP-seq or DNase-seq binding sites of
lipid-related regulatory features. GWAS -log10 P -values (Teslovich et al., 2010) are plotted in the
top panel. RegulomeDB SNP annotation scores of predicted regulatory elements are shown in the
second panel (Boyle et al., 2012). Purple dotted lines annotate the hypothesized functional variant
based on physical overlap prediction. Blue dotted lines annotate the control SNP, which is usually
the top most significant GWAS SNP. Regulatory elements highlighted in red annotate overlap with
the candidate functional variant.
A. SORT1 (sortilin 1). GWAS index SNP rs629301 is associated with LDL cholesterol and total
cholesterol.
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B. FAM117B (family with sequence similarity 117, member B). GWAS index SNP rs11694172
is associated with total cholesterol.
108
C. ANGPTL8 (Angiopoietin-like protein 8; C19orf80: chromosome 19 open reading
frame 80). GWAS index SNP rs737337 is associated with HDL cholesterol, and the candidate
functional SNP.
109
D. SPTLC3 (serine palmitoyltransferase, long chain base subunit 3). GWAS index SNP
rs364585 is associated with LDL cholesterol.
110
E. ADH5 (alcohol dehydrogenase 5 (class III), chi polypeptide). GWAS index SNP
rs2602836 is associated with HDL cholesterol. GWAS P -values here are reported from Global
Lipids Genetics Consortium et al. (2013).
111
F. IRF2BP2 (interferon regulatory factor 2 binding protein 2). GWAS index SNP rs514230
is associated with total cholesterol and LDL cholesterol.
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Figure 3.7: Luciferase assays with constructs containing non-coding SNP regions. Relative firefly
luciferase expression from constructs with haplotypes of 600-800 bp regions was transfected into
HepG2 cells. Single nucleotide alterations in each variant were introduced into constructs as indi-
cated and all luciferase activities were normalized to their pcDNA3.1 co-transfected control groups.
Nominal P -values and SD (n=8) for each SNP are shown. The PGL4 empty vector control is on
the far left, while the predicted functional variant and control variant follow next in each individual
locus figure.
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Table 3.1: Formulae for P -value calculation
Input
A SNP set of LD-pruned r GWAS index SNPs
Regulatory regions of interest formatted as BED files
m = number of control SNPs selected for each index SNP
SNP set i (1≤i≤r) = index SNP i and its m control SNPs
pi =




1, randomly drawn SNP from SNP set i falls in regulatory regions of interest
0, otherwise
Statistics Si ∼ Bernoulli(pi)
r∑
i=1
Si ∼ sum of r independent non-identical Bernoulli distribution
s = number of SNPs that falls in regulatory regions of interest in the input
GWAS index SNPs










A SNP is considered to fall in regulatory regions of interest if itself or any of its LD
proxies has positional overlap with the regions.
114
Feature	  1	  
SNP1	   SNP2	   SNP3	   SNP4	   SNP5	   SNP6	  
Identify	  set	  of	  independent	  trait-­‐associated	  SNPs	  and	  their	  LD	  proxies	  (r2	  >	  0.7)	  
Choose	  a	  feature	  containing	  experimentally	  identiDied	  regulatory	  regions	  identiDied	  by	  DNase-­‐seq	  or	  ChIP-­‐seq	  	  
Count	  observed	  overlap	  of	  each	  index	  SNP	  or	  its	  LD	  proxies	  with	  feature	  (k)	  
Feature	  1	  




∑ Pval = P(S ≥ k)
The	  number	  of	  index	  SNPs	  from	  all	  control	  sets	  that	  falls	  in	  a	  single	  feature	  is	  the	  sum	  of	  independent	  binomial	  random	  variables	  
#	  SNPs	  in	  the	  ith	  control	  set	  
ni	  =	  #	  index	  SNPs	  in	  the	  ith	  matched	  control	  set	  #	  SNPs	  or	  their	  LD	  proxies	  in	  ith	  control	  set	  that	  falls	  in	  feature	  pi	  =	  
si	  =	  #	  index	  SNPs	  in	  ith	  control	  set	  that	  overlaps	  a	  feature	  	  
Figure S3.1: Summary of GREGOR variant enrichment method.
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Figure S3.2: Enrichment of lipid-associated variation in DNase hypersensitive sites using different
parameter values. Tissues are ordered by decreasing P -value significance when using the parame-
ters r2=0.7 and matched control set size of 500.
(A) Magnitude of enrichment for a range of r2 thresholds. The r2 thresholds were used to select
1) the potential functional variants in LD with index variants using 1000 Genomes CEU and 2)
the control SNPs with approximately the same number of variants in LD as index variants (using













































































































































































































































(B) Magnitude of enrichment for matched control sets of various sizes. Matched control sets contain
variants that share the properties of 1) number of LD proxies, 2) minor allele frequency, and 3)




















































































































































































































































Figure S3.3: Comparison of enrichment P -values estimated using 10,000 permutations and the
sum of binomial trials as implemented in GREGOR. P -values less than 1x10-5 cannot be precisely
estimated by permutation testing, and so are excluded from the figure.
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Figure S3.4: Fold enrichment and enrichment P -values for lipid-associated variation in DNase
hypersensitive sites (DHSs) of different tissues and at different consensus thresholds. A consensus

























































































































































































































































































































































































Table S3.1: Experimentally identified DNase hypersensitivity sites of various tissues from ENCODE














































































































































































































Embryonic Embryonic Lung wgEncodeAwgDnaseUwWi38tamoxifentamoxifenUniPk.narrowPeak





Embryonic Embryonic Stem Cell wgEncodeAwgDnaseDukeH9esUniPk.narrowPeak
Stem Cell Embryonic Stem Cell wgEncodeAwgDnaseUwdukeH1hescUniPk.narrowPeak
Embryonic Stem Cell wgEncodeAwgDnaseUwH7hescUniPk.narrowPeak
Embryonic Stem Cell wgEncodeOpenChromDnaseH1hescPk.narrowPeak
Embryonic Stem Cell wgEncodeOpenChromDnaseH7esPk.narrowPeak
Embryonic Stem Cell wgEncodeOpenChromDnaseH9esPk.narrowPeak
Embryonic Stem Cell wgEncodeUwDnaseH1hescPkRep1.narrowPeak
Embryonic Stem Cell wgEncodeUwDnaseH7esDiffa14dPkRep1.narrowPeak
Embryonic Stem Cell wgEncodeUwDnaseH7esDiffa14dPkRep2.narrowPeak
Embryonic Stem Cell wgEncodeUwDnaseH7esDiffa2dPkRep1.narrowPeak
Embryonic Stem Cell wgEncodeUwDnaseH7esDiffa5dPkRep1.narrowPeak
Embryonic Stem Cell wgEncodeUwDnaseH7esDiffa5dPkRep2.narrowPeak
Embryonic Stem Cell wgEncodeUwDnaseH7esDiffa9dPkRep1.narrowPeak
Embryonic Stem Cell wgEncodeUwDnaseH7esPkRep1V2.narrowPeak
Embryonic Stem Cell wgEncodeUwDnaseH7esPkRep2.narrowPeak




















































Fetal Membrane Fetal Membrane wgEncodeAwgDnaseDukeChorionUniPk.narrowPeak
Fetal Membrane wgEncodeOpenChromDnaseChorionPk.narrowPeak

















Frontal Cerebrum Frontal Cerebrum wgEncodeOpenChromDnaseCerebrumfrontalocPk.narrowPeak

















IPS Induced Pluripotent Cell IPS wgEncodeOpenChromDnaseIpscwru1Pk.narrowPeak
Induced Pluripotent Cell IPS wgEncodeOpenChromDnaseIpsnihi11Pk.narrowPeak
Induced Pluripotent Cell IPS wgEncodeOpenChromDnaseIpsnihi7Pk.narrowPeak
Induced Pluripotent Stem Cell wgEncodeAwgDnaseDukeIpsUniPk.narrowPeak




































































Skeletal Skeletal Muscle Myoblast wgEncodeAwgDnaseUwdukeHsmmUniPk.narrowPeak
Muscle Skeletal Muscle Myoblast wgEncodeOpenChromDnaseHsmmPk.narrowPeak
Myoblast Skeletal Muscle Myoblast wgEncodeUwDnaseHsmmPkRep1.narrowPeak
Skeletal Muscle Myoblast wgEncodeUwDnaseHsmmPkRep2.narrowPeak
Skeletal Muscle Myoblast wgEncodeUwDnaseLhcnm2Diff4dPkRep1.narrowPeak
Skeletal Muscle Myoblast wgEncodeUwDnaseLhcnm2Diff4dPkRep2.narrowPeak
Skeletal Muscle Myoblast wgEncodeUwDnaseLhcnm2PkRep1.narrowPeak




















































Table S3.2: Enrichment of lipid loci in transcription factor binding sites and histone modifications














POLR2A 116 59.17 6.23x10-24
RCOR1 87 41.86 1.75x10-16
SP1 52 17.29 1.48x10-15
EP300 82 40.67 1.08x10-14 literature
eGFP JUND 86 43.98 2.20x10-14
H3K4me3 72 34.27 1.38x10-13 literature
MXI1 62 26.53 2.79x10-13
MYC 71 33.76 5.75x10-13
H3K36me3 52 20.55 1.07x10-12
MYBL2 39 11.69 1.17x10-12
TBL1XR1 63 29.30 8.89x10-12 lipid gene regulator
H3K9me1 111 70.65 2.11x10-11 literature
SMC3 63 30.21 2.57x10-11
ARID3A 68 34.44 3.44x10-11
H3k4me1 74 38.57 4.82x10-11
H3K9ac 56 25.49 1.25x10-10
MAZ 70 37.11 3.52x10-10
BHLHE40 67 34.86 4.42x10-10
TBP 57 27.07 4.95x10-10
eGFP GATA2 64 32.64 7.25x10-10
MAX 63 32.05 7.86x10-10
JUND 85 52.19 1.04x10-9
NCOR1 81 45.39 1.22x10-9 lipid gene regulator
FOXA1 46 20.41 5.00x10-9 lipid gene regulator
NFIC 48 21.88 6.26x10-9
TEAD4 44 19.11 7.09x10-9
TAL1 49 23.02 1.08x10-8
CEBPB 90 59.99 1.69x10-8 lipid gene regulator
CCNT2 49 23.51 1.99x10-8
HDAC2 33 12.05 2.13x10-8
HNF4G 26 7.82 2.19x10-8
RFX5 48 23.02 2.20x10-8
eGFP JUNB 52 25.73 2.39x10-8 literature
RXRA 25 7.50 4.23x10-8 lipid gene regulator
ELF1 40 17.21 4.38x10-8
JUN 61 34.37 1.08x10-7
CREB1 45 21.64 1.10x10-7 literature
CHD2 47 23.26 1.65x10-7
eGFP HDAC8 24 7.62 2.51x10-7
HMGN3 43 20.66 3.08x10-7
CUX1 40 18.64 4.04x10-7
ZNF143 51 27.20 4.49x10-7
CTCF 75 49.00 7.41x10-7
ZC3H11A 32 13.68 1.29x10-6
HNF4A 28 10.93 1.66x10-6 lipid gene regulator
IRF1 49 26.87 1.71x10-6
YY1 42 21.34 2.22x10-6 literature
TCF7L2 23 8.15 2.28x10-6 literature
USF2 30 12.76 2.98x10-6
MBD4 16 4.26 3.52x10-6















SIN3AK20 28 11.66 3.93x10-6
NFYA 20 6.79 7.28x10-6
SPI1 37 18.56 8.45x10-6
BRCA1 22 8.21 9.76x10-6
RAD21 52 31.14 1.22x10-5
SREBP1 11 2.29 1.40x10-5 lipid gene regulator
E2F6 35 17.56 1.48x10-5
HDAC1 22 8.52 1.85x10-5 literature
ZBTB7A 25 10.54 2.06x10-5
UBTF 32 15.91 3.31x10-5
HCFC1 38 20.75 4.65x10-5
TAF1 29 13.98 4.65x10-5
TCF12 20 7.85 7.83x10-5
E2F4 23 10.14 8.46x10-5
CEBPD 16 5.54 8.69x10-5 lipid gene regulator
EGR1 28 13.53 8.85x10-5
KDM5B 23 10.22 1.02x10-4
PML 32 17.10 1.42x10-4
RUNX3 40 23.82 2.09x10-4
USF1 26 12.74 2.12x10-4 lipid gene regulator
FOS 15 5.37 2.16x10-4
EBF1 31 16.38 2.26x10-4
FOXA2 29 15.33 2.86x10-4 lipid gene regulator
eGFP FOS 30 16.04 3.06x10-4
REST 25 12.46 3.30x10-4
FOSL2 20 8.83 3.60x10-4
GTF2F1 24 11.97 4.04x10-4
CHD1 20 9.14 4.59x10-4
eGFP NR4A1 11 3.50 6.68x10-4 literature
ATF1 35 21.01 6.95x10-4
POU2F2 21 10.12 7.41x10-4
SAP30 17 7.44 7.80x10-4
CEBPZ 6 1.17 9.52x10-4 literature
NR2F2 20 9.62 1.01x10-3
PHF8 25 13.65 1.24x10-3
MAFF 59 43.42 1.30x10-3
ELK1 20 10.04 1.66x10-3
MAFK 75 59.30 1.70x10-3
ATF3 16 7.46 2.48x10-3 literature
SREBP2 2 0.08 2.78x10-3 lipid gene regulator
GATA2 20 10.47 2.84x10-3
SIN3A 17 8.47 3.37x10-3
GTF2B 16 7.77 3.38x10-3
WRNIP1 16 7.77 3.60x10-3
ETS1 15 7.06 3.66x10-3
SIX5 9 3.16 3.80x10-3
KAP1 28 17.39 4.17x10-3
IRF4 16 8.10 5.70x10-3
CREBBP 87 70.93 5.90x10-3 lipid gene regulator
ZEB1 8 2.80 6.29x10-3
GTF3C2 7 2.27 6.98x10-3
PAX5 22 13.06 8.32x10-3















NR2C2 8 3.08 1.10x10-2 literature
NFYB 24 15.13 1.19x10-2
STAT1 10 4.52 1.36x10-2
RBBP5 18 10.59 1.50x10-2
FOSL1 9 4.03 1.76x10-2
GATA1 17 10.02 2.01x10-2
MTA3 15 8.61 2.25x10-2
SMARCA4 7 2.90 2.39x10-2
NRF1 11 5.69 2.43x10-2 lipid gene regulator
SIRT6 5 1.67 2.49x10-2 lipid gene regulator
ATF2 20 12.81 2.56x10-2 literature
STAT2 7 2.92 2.60x10-2
PBX3 8 3.77 3.30x10-2
H3k27me3 46 35.95 3.44x10-2 literature
SP2 6 2.54 4.05x10-2
ZBTB33 7 3.23 4.07x10-2
NFE2 5 1.92 4.19x10-2
CTCFL 7 3.29 4.60x10-2
BCLAF1 11 6.32 4.75x10-2
RPC155 3 0.88 5.83x10-2
STAT5A 15 10.13 7.48x10-2
STAT3 7 3.71 7.70x10-2
GRp20 2 0.50 8.75x10-2
THAP1 5 2.46 9.66x10-2
ZNF274 9 5.55 1.01x10-1
MEF2A 13 8.91 1.03x10-1
BACH1 12 8.42 1.30x10-1 literature
TAF7 5 2.74 1.36x10-1
IRF3 2 0.67 1.45x10-1 literature
BATF 14 10.35 1.46x10-1
RELA 12 8.71 1.57x10-1
ESRRA 2 0.72 1.59x10-1
TCF3 10 7.04 1.64x10-1
EZH2 5 3.06 1.91x10-1 literature
BCL3 10 7.33 1.95x10-1
IKZF1 8 6.00 2.50x10-1
MEF2C 6 4.34 2.63x10-1
SMARCB1 3 1.84 2.79x10-1
TRIM28 10 8.17 2.98x10-1 literature
NFATC1 9 7.25 2.99x10-1
HSF1 2 1.15 3.19x10-1
FOXM1 15 13.35 3.54x10-1 literature
SETDB1 8 6.90 3.84x10-1
RDBP 1 0.49 3.95x10-1
HDAC6 1 0.54 4.27x10-1
SRF 6 5.34 4.46x10-1
ZNF263 3 2.73 5.18x10-1
H3K9me3 116 119.5 7.73x10-1 literature
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Investigating the functional role of structural variation in
myocardial infarction risk from whole genome sequencing of
a Norwegian population
4.1 Abstract
Structural variation (SV) is a class of genetic variation whose implication in com-
plex disease is currently not well understood. We investigate the role of deletions,
duplications, and inversions in risk for heart disease within a cohort of 2,202 Norwe-
gians from The HUNT Study, which includes cases with myocardial infarction (MI)
and matched controls. Using complementary approaches for discovering structural
variation from whole genome sequencing data, we identify SVs in the Norwegian pop-
ulation and perform genome wide association analyses with myocardial infarction and
quantitative lipid traits. We confirm linkage disequilibrium between a deletion on
chromosome 2 and a single variant associated with MI at the WDR12 locus. Struc-
tural variants identified by this study can be used for imputation into the larger
HUNT cohort for increased power to detect significant associations.
4.2 Introduction
Early-onset myocardial infarction (MI) is a major cause of mortality in the U.S.
and throughout the world, with both common and rare genetic mutations contribut-
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ing to its multifactorial risk (Mozaffarian et al., 2015). GWAS efforts over the past
8 years have led to discoveries of over 50 single genetic risk variants associated with
coronary artery disease (CAD) or MI (McPherson et al., 2007; Samani et al., 2007;
Helgadottir et al., 2007; Myocardial Infarction Genetics Consortium et al., 2009;
Schunkert et al., 2011; Coronary Artery Disease (C4D) Genetics Consortium, 2011;
IBC 50K CAD Consortium, 2011; CARDIoGRAMplusC4D Consortium et al., 2013;
CARDIoGRAMplusC4D Consortium et al., 2015). According to the latest meta-
analysis involving nearly 185,000 participants, single variants identified by genome
wide association studies together explain 12.9 ± 0.4% of the trait heritability for
CAD (CARDIoGRAMplusC4D Consortium et al., 2015). Do et al. (2015) used ex-
ome sequencing to find that the burden of rare mutations in APOA5 and LDLR
explains 0.14% and 0.24% of the total variance for MI and roughly 0.28% and 0.48%
of the heritability, respectively. Many of these risk loci contain variants associated
with LDL cholesterol (LPA, APOB, SORT1, LDLR, APOE, ABCG5-ABCG8, and
PCSK9 ), HDL cholesterol (ANKS1A), and triglycides (TRIB1 and APOA5-A4-C3-
A1 ), suggesting a plausible role of lipid modulation in disease risk (Roberts, 2015).
Still, for other disease-associated loci, the risk mechanism remains unclear.
Our current understanding of the functional role of structural variation (SV) in
myocardial infarction is in its infancy relative to simpler forms of genetic variation.
These balanced or unbalanced copy number changes, typically defined as 50 base
pairs to several kb in size, have traditionally been discovered using array-based (Mc-
Carroll et al., 2008; Conrad et al., 2010) and clone-based methods (Kidd et al.,
2008). For example, Conrad et al. (2010) used array CGH to report a CNV in
LD with a variant at the MI-risk locus, WDR12. Advances in sequencing tech-
nology have prompted the development of methods for discovering and genotyping
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structural variants at higher resolution (Mills et al., 2011; Sudmant et al., 2015).
Whole-genome sequencing allows for a finer interrogation of the genome to discover
structural variants, including low frequency and rare copy number events.
Using whole-genome sequencing in a Norwegian population of 2,202 matched MI
cases and controls, we investigate whether structural variation plays a functional
role in myocardial infarction risk and regulation of quantitative lipid traits. We
hypothesize that there are different frequencies of structural variants in MI cases
compared to controls and apply established and complementary SV detection algo-
rithms to discover and genotype deletions, duplications, and inversions. We carry
out a genome wide association study framework to test for associations that will
implicate structural variation in heart disease risk.
4.3 Methods
4.3.1 Phenotype measurements
The population-based Nord-Trøndelag Health Study (The HUNT Study) is a col-
laboration between the HUNT Research Centre (Faculty of Medicine, Norwegian Uni-
versity of Science and Technology NTNU), Nord-Trøndelag County Council, Central
Norway Health Authority, and the Norwegian Institute of Public Health (Krokstad
et al., 2013). A set of 2,202 Norwegian individuals was chosen from the Nord-
Trøndelag Health study for whole genome sequencing. Sequenced participants were
composed of 1,101 cases with early-onset MI, and 1,101 healthy controls that were
one-to-one matched on age, sex, and birth municipality. The earliest-onset cases,
primarily from batch 1 (see Section 4.3.2), were defined as an MI event at age ≤ 55
years for males and ≤ 65 years for females (Figure 4.1). Controls were chosen from
cohort participants without self-reported and/or hospital diagnosed MI, MI in first-
or second-degree family members, cardiovascular disease, diabetes, or hypertension.
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No sequenced individuals had any known first- or second-degree relatives among the
others selected for sequencing.
We also collected directly-measured lipid phenotypes including non-fasting plasma
HDL cholesterol, triglycerides, and total cholesterol (Table 4.1). LDL cholesterol
levels for participants with triglyceride levels <400 mg/dL were estimated using the
Friedewald formula, as shown in Equation 4.1 (Friedewald et al., 1972).
(4.1) LDL-C = TC − HDL-C − TG
5
Lipid measurements were collected on the same samples at two time points approx-
imately 10 years apart as included in the HUNT2 (1995-97) and HUNT3 (2006-08)
efforts. Residuals estimated from each HUNT stage were averaged for the association
analysis (see Section 4.3.4).
4.3.2 Whole-genome sequencing
Illumina-based whole-genome sequencing (∼100 bp reads) of 2,202 samples was
performed at the University of Michigan DNA Sequencing Core in 3 batches over
a 3-year period. Equal numbers of MI cases and controls in batches 1 (n=602), 2
(n=800), and 3 (n=800) were sequenced with total average coverage of 5.9x, 5.4x,
and 4.3x, respectively. A subset of individuals (n=210) was also targeted for exome
sequencing, but the targeted sequencing was removed from these samples for the
subsequent analysis. Differences in library preparation protocol resulted in varying
insert size distributions between samples (Figure 4.2) and across batch (Figure 4.3),
with batch 1 samples generally having smaller insert sizes than batch 2 and 3 sam-
ples. Insert size standard deviations differ by batch but not by case-control sta-
tus (Figure 4.4). Sequence alignment was performed using the GotCloud pipeline
(http://genome.sph.umich.edu/wiki/GotCloud).
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4.3.3 Structural variant calling
Deletions were called and genotyped by integrating several technical features of
the sequence data as well as population-scale patterns across the 2,202 genomes
analyzed (GenomeSTRiP 2.0, Handsaker et al. (2015)). In brief, GenomeSTRiP in-
corporates information from break-point spanning reads, paired-end sequences, and
local variation in read depth coverage to discover deletions with improved sensitivity
and specificity relative to other algorithms that use only one or two of these fea-
tures. To improve upon the power to detect structural variation in a single genome,
GenomeSTRiP considers how alleles are shared across multiple genomes and patterns
of sequence heterogeneity to accurately determine the state of each variant in every
individual genome of the population. Six HUNT individuals with an outlier number
of variants by this method were removed from the subsequent association analysis
(Figure 4.5).
Deletions (DEL), tandem duplications (DUP), and inversions (INV) were also
called per individual whole-genome targeted sample using a read-pair and split-read
based method (DELLY, Rausch et al. (2012)). By integrating the paired-end and
split-read alignments, DELLY can delineate copy-number variable events as well as
balanced rearrangements such as inversions. The human reference genome containing
decoy sequence (to remove reads that would otherwise map with low quality in the
reference) was downloaded from ftp://ftp-trace.ncbi.nih.gov/1000genomes/
ftp/technical/reference/phase2_reference_assembly_sequence/, and telom-
eric and centromeric regions were excluded in SV calling. Counts of events called
by mean sequencing depth show that batch 1 samples with tighter insert size dis-
tributions generally called more deletions than samples from the other two batches
(Figure 4.6). Structural variants that passed the DELLY quality filter were com-
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bined across all 2,202 sequenced samples by merging events that overlapped by 80%
reciprocally. Genotypes were combined by assuming that the absence of a variant in
the overlapping region implies homozygous reference genotypes.
Finally, we used the HUNT metadata information from GenomeSTRiP to geno-
type the merged DELLY deletions, as well as those deletions called from the 1000
Genomes Project Phase 3 v5 (1000 Genomes Project Consortium et al., 2012).
We examined whether SVs were in strong linkage disequilibrium (LD) with previ-
ously reported CAD- or lipid-associated SNPs in the 2,202 sample HUNT population.
Pairwise r 2 was estimated between each SV and the GWAS-reported index SNP us-
ing best-guess unphased genotypes.
4.3.4 Association analysis
Association analyses were carried out separately for deletions, duplications, and
inversions using PLINK. We performed logistic regression of MI case-control response
and genotype predictors with minor allele frequency (MAF) >0.01 (minor allele count
>44). We adjusted for covariates age, sex, and batch, as well as the first 10 principle
components (PCs) estimated from sequence genotypes of the 2,202 sequenced samples
(Equation 4.2).
(4.2) MI status = SV genotype + birth year + sex+ batch+ PC1−PC10
We also performed association analysis of SV genotypes with quantitative lipid
traits HDL-C, LDL-C, TG, and TC. Inverse normalized residuals for each of the
four lipid traits were generated separately for each HUNT time point (HUNT2 and
HUNT3) with adjustment for birth year and sex. Estimated residuals from the two
HUNT stages were then averaged (Figure 4.7) and used as the response in a linear
regression (Wald test) with adjustment for covariates MI status, batch, and 10 PCs
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(Equation 4.3).
Birth year- and sex-adjusted inverse normalized residuals =
SV genotype + MI status + batch+ PC1−PC10
(4.3)
Association analyses in this manner were carried out separately for genotype calls
with MAF >0.01 for deletions (from DELLY, GenomeSTRiP, and 1000 Genomes
separately), duplications, and inversions that were <1Mb in size.
After checking for cryptic relatedness using genotype information, one individual
was found to be contaminated and removed from the association analysis in addition
to the six samples with outlier SV calls (see Section 4.3.3). Table 4.2 describes the
final counts of individuals used for association with each trait based on QC and
phenotype availability.
A schematic diagram of the overall SV analysis pipeline is provided in Figure 4.8.
4.4 Results
We discovered a set of 3,270 deletions (885 2kb-1Mb) with MAF>0.01 in the
HUNT population using GenomeSTRiP, as well as 5,564 deletions (1,209 2kb-1Mb),
723 duplications (218 2kb-1Mb), and 493 inversions (183 2kb-1Mb) with MAF>0.01
from DELLY (Table 4.3). We found 252 deletions called in the 1000 Genomes Project
Phase 3 v5 that overlapped by 80% reciprocally with those deletions discovered in
the HUNT population. Distributions of association P -values for MI status and each
quantitative lipid trait are shown in Figures 4.9-4.13. The red P -value distributions
in each of these figures represents SVs within 1Mb of any GWAS single variant,
while all other variants are shown in black. Known GWAS variants are defined
as published variants associated with any of the four lipid traits, published CAD-
associated variants, and a set of novel lipid-associated variants identified from an
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ongoing exome chip study (Liu and Global Lipids Genetics Consortium, 2014). We
did not observe genome-wide significant associations (based on Bonferroni correction
for the number of tests) with either MI status or lipids (see top significant results in
Tables 4.5-4.7).
Of those 34 CNVs reported by Conrad et al. (2010) with tagged GWAS SNPs,
we found 15 nearby CNVs in the HUNT population as well as in the 1000 Genomes
Project (Table 4.4). Both DELLY and GenomeSTRiP called a deletion (2:203898933-
203904481 and 2:203899034-203904285, respectively) near the Conrad et al. (2010)
deletion tagging an MI-associated SNP at the WDR12 locus. Estimation of linkage
disequilibrium between this SNP (rs6725887; chr2:203745885) and the GenomeSTRiP
genotypes at this deletion (DEL P0227 516; chr2:203899034-203904285) confirmed
their strong linkage disequilibrium (r 2=0.98) (Figure 4.14).
4.5 Discussion
Several conclusions can be drawn from this research including both biological
insights and computational lessons. Sequencing experimental protocol can largely
affect SV calling, particularly when there is insert size variability between samples.
In our study, the 210 samples that were targeted for exome sequencing in addition
to whole genome sequencing had systematically smaller insert sizes, which biased
deletion calling to smaller events. To eliminate this bias, we excluded the targeted
exome from these individual samples and kept only the sequenced whole genomes
for SV discovery, genotyping and subsequent analysis.
In addition, the differences in insert size distributions due to changes in library
preparation protocol over the sequencing time period resulted in a bias toward calling
more small deletions in batch 1 samples (Figure 4.2). Library construction with the
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epMotion robotic workstation used gel size selection, which resulted in more consis-
tent insert sizes of the first 576 batch 1 samples. In contrast, the IntegenX library
prep protocol used bead size selection for the remaining samples, which resulted in
much broader insert size distributions. In paired-end sequencing, fragments are ex-
pected to be consistently mapped a particular distance away from each other. A
discrepancy in this distance indicates a structural variation between the paired-end
tag sequences. For example, a deletion in a sequenced genome will have reads that
map further away than expected in the reference genome, since the reference genome
will have a DNA fragment that is missing in the sequenced genome. Consequently,
variability in size of the sequenced fragments, as produced in the IntegenX-prepped
samples, reduces the ability to distinguish small deletion events that deviate from the
reference genome. For duplications and inversions however, the numbers of events
called were more similar across batch. This is expected since these events were called
based on the orientation of mapped reads rather than relying on insert size. We ad-
dressed this technical sequencing artifact by adjusting for batch in the association
analysis.
Different genotyping approaches give variable results, suggesting the necessity to
explore more than one method when studying structural variation. Taking into ac-
count the sequence heterogeneity across multiple individuals gives GenomeSTRiP an
advantage over other methods, especially when sequencing a sizable cohort. Indeed,
we observed more significant deletions by this method than the alternative DELLY
approach. This supports the power of harnessing patterns of sequence heterogene-
ity within a population and integrating paired-end, split-read, and read-depth-based
analyses. Sequencing a large number of individuals is a study design that is becoming
increasingly more feasible as sequencing costs decline, and we have seen the success-
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ful performance of the GenomeSTRiP approach in the 1000 Genomes Project effort
(1000 Genomes Project Consortium et al., 2012). In addition to calling deletions,
however, the DELLY approach of integrating paired-end and split-read alignments is
advantageous in that it can call tandem duplications and balanced rearrangements.
Thus, by applying these complementary approaches, we were able to investigate a
broad spectrum of genomic rearrangements in the HUNT population.
The choice of algorithm for discovery and genotyping of structural variation may
depend on the goals and design of a particular study. For example, in a study for
which the primary objective is to discover novel events, taking the union of SV events
discovered by both DELLY and GenomeSTRiP would give the most comprehensive
set. Where accurate genotyping is of primary concern in a study, genotyping using
GenomeSTRiP is the superior choice. To illustrate this, we estimated linkage dise-
quilibrium in the HUNT samples between previously reported (Conrad et al., 2010)
trait-associated SNPs and their tagged CNV’s. DELLY genotypes consistently re-
sulted in low r 2 estimates (Table 4.4). On the other hand, GenomeSTRiP replicated
these LD relationships much more consistently. This suggests that DELLY geno-
types are less reliable and perhaps contain an excess of false negatives, calling events
as more rare than the truth. Given the insights from this study, thoughtful consid-
eration should be made when choosing a method for structural variation analysis of
sequencing data.
Careful study design of matched cases and controls, adjusting for appropriate
confounders such as age and sex, and applying the appropriate transformation of
quantitative lipid measurements are all critical for identifying true causal associa-
tions. Filtering sites based on the quality scores of the respective calling methods is
critical to identify a confident set of events and prevent false positive associations.
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Our regression results suggest that structural variation does not play a strong role in
MI risk and modulating lipid levels. However, the absence of significant large-effect
associations for MI and lipids does not suggest an absent role of structural varia-
tion in modulating these phenotypes, but rather that we are underpowered to detect
them. To increase our power for discovery in the future, structural variants identi-
fied here will be imputed into the larger HUNT cohort of 30,000 samples for further
study. A comprehensive survey of linkage disequilibrium between structural varia-
tion and GWAS-reported single markers did not reveal additional SV-single marker
LD relationships. Again, a larger cohort may be needed to identify SVs that tag
single markers to suggest novel plausible functional candidates.
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Figure 4.1: Distribution of age at MI onset in 1,101 affected individuals by batch.
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Figure 4.2: Insert size distributions for different library preparation methods. Most batch 1 samples
(n=576) were prepped using the epMotion robotic workstation and the remaining samples were
prepped using the IntegenX robotic workstation (batch 1, n=26; batch 2, n=800; batch 3, n=800).
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Figure 4.3: Insert size distributions colored by batch. Sequencing data were processed over 3 years
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Figure 4.7: Distribution of age- and sex-adjusted residuals for lipids. Residuals were estimated
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Figure 4.8: Structural variant analysis pipeline.
149
Figure 4.9: SV association results for MI status. Logistic regression of HUNT genotypes with MI
status was carried out separately for (A) deletions discovered by GenomeSTRiP, DELLY, and the
1000 Genomes Project; (B) duplications discovered by DELLY; and (C) inversions discovered by
DELLY. QQplots show association P -values for structural variants within 1Mb (red) and outside
1Mb (black) of known CAD- or lipid-associated GWAS SNPs.
A. DELETIONS























































































































































































































































































































































































































































































































































































































B. DUPLICATONS C. INVERSIONS



































































































































































































































































































Figure 4.10: SV association results for LDL cholesterol. Linear regression of HUNT genotypes
with LDL cholesterol was carried out separately for (A) deletions discovered by GenomeSTRiP,
DELLY, and the 1000 Genomes Project; (B) duplications discovered by DELLY; and (C) inversions
discovered by DELLY. QQplots show association P -values for structural variants within 1Mb (red)
and outside 1Mb (black) of known CAD- or lipid-associated GWAS SNPs.
A. DELETIONS












































































































































































































































































































































































































































































































































































B. DUPLICATONS C. INVERSIONS














































































































































































































































































Figure 4.11: SV association results for HDL cholesterol. Linear regression of HUNT genotypes
with HDL cholesterol was carried out separately for (A) deletions discovered by GenomeSTRiP,
DELLY, and the 1000 Genomes Project; (B) duplications discovered by DELLY; and (C) inversions
discovered by DELLY. QQplots show association P -values for structural variants within 1Mb (red)
and outside 1Mb (black) of known CAD- or lipid-associated GWAS SNPs.
A. DELETIONS
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Figure 4.12: SV association results for triglycerides. Linear regression of HUNT genotypes with
triglycerides was carried out separately for (A) deletions discovered by GenomeSTRiP, DELLY, and
the 1000 Genomes Project; (B) duplications discovered by DELLY; and (C) inversions discovered
by DELLY. QQplots show association P -values for structural variants within 1Mb (red) and outside
1Mb (black) of known CAD- or lipid-associated GWAS SNPs.
A. DELETIONS























































































































































































































































































































































































































































































































































































B. DUPLICATONS C. INVERSIONS




































































































































































































































































Figure 4.13: SV association results for total cholesterol. Linear regression of HUNT genotypes
with total cholesterol was carried out separately for (A) deletions discovered by GenomeSTRiP,
DELLY, and the 1000 Genomes Project; (B) duplications discovered by DELLY; and (C) inversions
discovered by DELLY. QQplots show association P -values for structural variants within 1Mb (red)
and outside 1Mb (black) of known CAD- or lipid-associated GWAS SNPs.
A. DELETIONS
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Figure 4.14: HUNT single variant MI association results at the WDR12 locus. There is a 5,251 base-
pair deletion (highlighted in red) in linkage disequilibrium (r2=0.98) with the previously reported
MI-associated index SNP rs6725887 (colored in purple).
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Table 4.1: Phenotype descriptive statistics for HUNT sequenced samples
Descriptive statistics for sex
Male Female Overall
Sex Case 756 345 1101
Control 756 345 1101
Overall 1512 690 2202
Descriptive statistics for agea and quantitative lipid measurementsb
Min Mean Median Max
Age at participation (years) Case 20.00 54.55 54.00 82.00
Control 20.00 53.66 53.00 81.00
Overall 20.00 54.11 54.00 82.00
LDL cholesterol (mg/dL) Case 21.10 127.30 122.10 345.70
Control 43.32 148.20 145.90 293.90
Overall 21.1 138.0 135.4 345.7
HDL cholesterol (mg/dL) Case 19.3 45.9 42.5 104.2
Control 23.20 52.72 50.20 115.80
Overall 19.30 49.31 46.30 115.80
Triglycerides (mg/dL) Case 35.4 186.4 159.3 1443.0
Control 35.4 149.3 129.6 902.7
Overall 35.4 167.6 141.6 1443.0
Total cholesterol (mg/dL) Case 81.1 209.5 204.6 432.4
Control 123.6 230.2 227.8 382.2
Overall 81.1 219.9 216.2 432.4
aAge from HUNT2; HUNT3 age was used when HUNT2 age was not available.
bLipid measurements were averaged from HUNT2 and HUNT3;
HUNT3 measurements were used when HUNT2 data were not available.
156
Table 4.2: Sample sizes for association analysis by trait
Trait Samples that pass QC Non-missing phenotypes Total samples in analysis
MI 2195 2202 2195
LDL-C 2195 2134 2127
HDL-C 2195 2201 2194
TC 2195 2201 2194



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 4.5: Top significant association results for deletions
Locus Chr Start End Trait OR/Effect Size P-value Source
OR5P2 11 7790133 7792078 MI 0.7857 1.49x10-4 DELLY
AGMO 7 15229569 15230065 MI 0.7224 3.50x10-4 DELLY
UBE2NL X 143406811 143410134 MI 0.7496 6.18x10-4 DELLY
PFDN4 20 52866065 52867491 MI 0.3224 7.79x10-4 DELLY
WDR47 1 109573112 109575345 MI 0.7800 1.21x10-3 DELLY
CDH6 5 30915523 30916059 MI 0.7668 2.16x10-4 GenomeSTRiP
LONP2 16 48311331 48311679 MI 0.7167 2.30x10-4 GenomeSTRiP
MIR548AE2 14 30817195 30819456 MI 1.9680 9.93x10-4 GenomeSTRiP
G2E3 7 52963199 52964915 MI 0.6465 1.69x10-3 GenomeSTRiP
POM121L12 9 22653155 22653781 MI 0.5957 2.21x10-3 GenomeSTRiP
LINC01239 11 5760086 5762366 MI 0.7813 1.02x10-4 1000G
OR56B1 5 30915526 30916063 MI 0.7702 2.69x10-4 1000G
CDH6 14 30817188 30819455 MI 1.9110 1.50x10-3 1000G
G2E3 1 188539457 188540228 MI 0.7600 2.05x10-3 1000G
BRINP3 19 23465135 23466785 MI 1.2360 2.63x10-3 1000G
IPO5P1 5 86245887 86247320 LDL-C -0.25 1.19x10-4 DELLY
MIR4280 9 19671646 19673613 LDL-C -0.26 1.97x10-4 DELLY
SLC24A2 X 124115599 124116298 LDL-C -0.32 4.98x10-4 DELLY
TENM1 13 85929413 85929777 LDL-C -0.27 8.91x10-4 DELLY
LINC00351 11 51340884 51363219 LDL-C -0.09 9.81x10-4 DELLY
OR4A5 4 92472837 92478295 LDL-C 0.64 6.41x10-7 GenomeSTRiP
CCSER1 10 42454653 42457078 LDL-C 0.44 4.97x10-6 GenomeSTRiP
LOC441666 10 91998535 92002030 LDL-C 0.52 5.14x10-5 GenomeSTRiP
RP11-15K3 5 45192227 45194396 LDL-C 0.56 8.49x10-5 GenomeSTRiP
HCN1 12 38335811 38341301 LDL-C 0.53 1.44x10-4 GenomeSTRiP
ALG10B 4 92472835 92478331 LDL-C 0.66 3.78x10-7 1000G
MLLT3 9 20380045 20386726 LDL-C 0.68 2.66x10-6 1000G
MIR1973 4 117499720 117503035 LDL-C 0.62 3.63x10-6 1000G
HCN1 5 46217822 46219362 LDL-C 0.46 1.77x10-5 1000G
RAB9BP1 5 104949722 104955603 HDL-C 0.59 2.42x10-5 1000G
UGT2B7 4 69959686 69960320 HDL-C -0.15 9.35x10-5 DELLY
TMPRSS11E 4 69373294 69491273 HDL-C -0.23 3.04x10-4 DELLY
PPP2R5E 14 63887380 63887889 HDL-C -0.26 3.17x10-4 DELLY
KIRREL3-AS3 11 127456167 127456578 HDL-C -0.19 6.08x10-4 DELLY
IL1RAPL1 X 29821144 29821508 HDL-C 0.38 7.88x10-4 DELLY
TMEM248 7 66397601 66397942 HDL-C 0.47 2.84x10-5 GenomeSTRiP
MIR5011 18 64959011 64967266 HDL-C -0.32 3.48x10-4 GenomeSTRiP
P2RY8 X 1667032 1667328 HDL-C 0.23 3.60x10-4 GenomeSTRiP
SCARB1 12 125334384 125334699 HDL-C -0.08 6.74x10-4 GenomeSTRiP
MYO9A 15 72126376 72126737 HDL-C 0.30 9.54x10-4 GenomeSTRiP
ZBTB11 3 101357527 101359730 HDL-C -0.13 5.41x10-5 1000G
MIR5011 18 64958984 64967256 HDL-C -0.32 3.48x10-4 1000G
LOC101928401 7 56652469 56658519 HDL-C 0.09 6.09x10-4 1000G
KIAA1257 3 128672140 128675334 HDL-C -0.40 8.30x10-4 1000G
SOX5 12 23939446 23940212 HDL-C 0.13 1.43x10-3 1000G
TRIM49B 11 48944428 48945723 TG -0.12 3.63x10-5 DELLY
TPO 2 1533816 1536862 TG -0.10 2.70x10-4 DELLY
TSHR 14 81596902 81597479 TG 0.33 5.93x10-4 DELLY
TRIM48 11 54869785 54871917 TG -0.22 8.97x10-4 DELLY
MIR5007 13 55634075 55634428 TG -0.25 9.66x10-4 DELLY
ARHGEF18 19 7451063 7454115 TG -0.47 1.33x10-4 GenomeSTRiP
SLC35F3 1 234318643 234319750 TG 0.14 1.06x10-3 GenomeSTRiP
GPC5 13 93000122 93000324 TG 0.13 1.11x10-3 GenomeSTRiP
PLOD2 3 145644968 145649191 TG 0.09 1.14x10-3 GenomeSTRiP
CACNA1A 19 13301205 13301539 TG -0.12 1.77x10-3 GenomeSTRiP
ARHGEF18 19 7451039 7454104 TG -0.47 1.33x10-4 1000G
LOC647859 5 70368390 70391629 TG -0.11 7.81x10-4 1000G
SLC35F3 1 234318645 234319749 TG 0.14 1.25x10-3 1000G
RASSF2 20 4807411 4808147 TG -0.24 1.55x10-3 1000G
PLOD2 3 145644966 145649185 TG 0.09 1.94x10-3 1000G
OR4A5 11 51340884 51363219 TC -0.09 3.40x10-4 DELLY
MIR4280 5 86245887 86247320 TC -0.22 3.42x10-4 DELLY
TENM1 X 124115599 124116298 TC -0.31 3.49x10-4 DELLY
LOC100129138 1 105667371 105668654 TC 0.18 4.98x10-4 DELLY
AKAP6 14 32953126 32954531 TC -0.23 7.87x10-4 DELLY
CCSER1 4 92472837 92478295 TC 0.66 3.68x10-8 GenomeSTRiP
ALG10 12 34709011 34715660 TC 0.36 6.34x10-6 GenomeSTRiP
RP11-15K3 10 91998535 92002030 TC 0.51 1.59x10-5 GenomeSTRiP
LOC441666 10 42454653 42457078 TC 0.39 1.63x10-5 GenomeSTRiP
ALG10 12 34685528 34696065 TC 0.37 1.97x10-5 GenomeSTRiP
CCSER1 4 92472835 92478331 TC 0.68 1.51x10-8 1000G
MLLT3 9 20380045 20386726 TC 0.71 1.30x10-7 1000G
RAB9BP1 5 104949722 104955603 TC 0.63 1.08x10-6 1000G
HCN1 5 46217822 46219362 TC 0.48 1.44x10-6 1000G
LINC00293 8 47216305 47233060 TC 0.56 1.62x10-6 1000G
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Table 4.6: Top significant association results for duplications
Locus Chr Start End Trait OR/Effect Size P -value Source
GALNT9 12 132973788 132974587 MI 1.6490 2.27x10-3 DELLY
GALNT9 12 132973707 132974587 MI 1.5790 4.44x10-3 DELLY
PDX1 13 28508684 28509249 MI 1.4260 5.68x10-3 DELLY
DNAH14 1 225133308 225248377 MI 0.6307 6.20x10-3 DELLY
C9orf106 9 132158710 132159317 MI 1.2630 6.99x10-3 DELLY
AKAP11 13 42947269 42947736 LDL-C 0.13 1.95x10-3 DELLY
AKAP11 13 42947268 42947736 LDL-C 0.13 2.01x10-3 DELLY
EPS8L2 11 711724 712153 LDL-C -0.41 3.73x10-3 DELLY
EPS8L2 11 711722 712153 LDL-C -0.38 5.19x10-3 DELLY
LINC00473 6 166253236 166253588 LDL-C -0.27 6.69x10-3 DELLY
COL5A1 9 137576794 137577726 HDL-C 0.10 1.59x10-3 DELLY
HLA-DRB5 6 32469530 32540210 HDL-C 0.06 3.17x10-3 DELLY
COL5A1 9 137576781 137577726 HDL-C 0.09 5.10x10-3 DELLY
ADARB1 21 46575840 46576486 HDL-C 0.07 5.39x10-3 DELLY
CNTNAP5 2 125766561 125768484 HDL-C 0.08 5.65x10-3 DELLY
SORBS1 10 97206785 97208113 TG -0.09 8.78x10-3 DELLY
TCEA3 1 23718825 23719261 TG -0.21 9.28x10-3 DELLY
PITRM1 10 3356380 3357458 TG -0.21 1.31x10-2 DELLY
KLK7 19 51484077 51484767 TG -0.09 1.39x10-2 DELLY
EPS8L2 11 711724 712153 TG -0.31 1.48x10-2 DELLY
EPS8L2 11 711724 712153 TC -0.41 2.15x10-3 DELLY
C3orf38 3 88547135 88547974 TC -0.23 3.68x10-3 DELLY
LMCD1 3 8601108 8601876 TC 0.18 4.43x10-3 DELLY
EPS8L2 11 711722 712153 TC -0.36 5.43x10-3 DELLY
LOC644172 17 43655785 44366773 TC 0.20 9.27x10-3 DELLY
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Table 4.7: Top significant association results for inversions
Locus Chr Start End Trait OR/Effect Size P -value Source
DPM3 1 155119792 155120021 MI 0.4367 3.47x10-4 DELLY
DPM3 1 155119740 155120021 MI 0.4374 7.16x10-4 DELLY
CCDC129 7 31586877 31590353 MI 1.3310 1.33x10-3 DELLY
DPM3 1 155119793 155120021 MI 0.5049 1.38x10-3 DELLY
ZNF626 19 20801073 20884244 MI 0.8509 2.27x10-3 DELLY
LCMT1 16 25204035 25204734 LDL-C -0.26 2.41x10-3 DELLY
SLC25A51P1 6 67492324 67492651 LDL-C -0.26 6.69x10-3 DELLY
RASGRP3 2 33764621 33768033 LDL-C -0.15 7.13x10-3 DELLY
TPTE2P6 13 25154598 25542722 LDL-C 0.07 9.87x10-3 DELLY
PLEKHB2 2 131886576 131887696 LDL-C 0.10 1.17x10-2 DELLY
KLC2 11 66019004 66020102 HDL-C 0.10 1.04x10-3 DELLY
SFTPA2 10 81316454 81374513 HDL-C 0.12 3.63x10-3 DELLY
MIR3924 10 59257657 59258202 HDL-C 0.05 5.66x10-3 DELLY
AUTS2 7 70420815 70438968 HDL-C 0.05 1.02x10-2 DELLY
RAD51B 14 68907825 69298024 HDL-C 0.16 1.16x10-2 DELLY
NCKAP5L 12 50182514 50183034 TG 0.12 1.49x10-4 DELLY
PRSS35 6 84207259 84610844 TG -0.28 4.72x10-3 DELLY
ASIC2 17 31683859 31684175 TG -0.27 6.83x10-3 DELLY
ARID1B 6 157559436 157641398 TG 0.13 6.91x10-3 DELLY
MGLL 3 127496284 127497985 TG -0.15 8.24x10-3 DELLY
RASGRP3 2 33764621 33768033 TC -0.15 3.18x10-3 DELLY
MYCN 2 16406391 16407874 TC -0.10 6.90x10-3 DELLY
LOC644172 17 43663171 44338245 TC 0.15 9.49x10-3 DELLY
SLC25A51P1 6 67492324 67492651 TC -0.23 1.01x10-2 DELLY




Our collective knowledge of the role of human genetic variation in complex disease
has come a long way since the first published genome-wide association studies. As
a research community, we’ve catalogued over 150 common variants and at least 25
loci containing rare variants that influence lipid variability in humans. We’ve made
advances in identifying functional variants at associated loci and recognized the reg-
ulatory importance of noncoding variation. In addition, we’ve been able to leverage
genetic tools to answer questions about the clinical implications of lipid-associated
variants. Together, these insights provide the groundwork for individualized treat-
ment, diagnosis, and prevention of heart disease. Through this dissertation research,
I have advanced our understanding of lipid genetics and developed a tool that has ex-
panded our knowledge of the biological mechanisms underlying noncoding variation
associated with lipids as well as other complex traits.
In the manuscript Global Lipids Genetics Consortium et al. (2013), a follow-up
study of 100,000 individuals genotyped on Metabochip, we discovered 62 novel ge-
netic loci associated with lipids to contribute to the existing list of known associated
loci. Chapter II described the discovery of these loci and several downstream analy-
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ses including pathway analyses, investigation of regulation of mRNA expression, and
literature review that support the roles of 38 of these loci in regulation of plasma
lipids. The mechanistic role of the remaining loci is unknown, leaving considerable
opportunity for functional insights from genetic studies in the coming years. Given
the non-protein-coding role of so many lipid-associated variants reported by GWAS,
I developed a tool in Chapter III to evaluate the enrichment of GWAS variants
in tissue-specific chromatin states and regulatory features defined by bioinformatics
techniques and new sequencing approaches such as ChIP-seq (Schmidt et al., 2015).
Using a data-driven hypothesis, I selected particular variants at a set of five lipid
loci as the potential functional variant, and reported experimental luciferase results
to confirm my computational predictions. Lastly, in Chapter IV I performed discov-
ery and genotyping of insertions, duplications, and inversions from low-pass whole
genome sequencing of nearly 2,000 Norwegian MI-cases and controls. Although we
did not have the power to detect significant genome-wide associations with struc-
tural variants identified in this dataset, I learned many technical and computational
lessons including the importance of accurate sequencing library preparation for CNV
calling, and generating an optimal SV analysis pipeline using complementary geno-
typing approaches.
5.2 Interpreting GWAS: promises and challenges
Despite the strides we have made in understanding lipid genetics, there are still
shortcomings to traditional genome-wide association study designs and an incomplete
knowledge of the biological mechanisms underlying GWAS-identified signals. Firstly,
GWA studies are primarily designed for finding common trait-associated variation,
but natural selection has reduced the frequency of high-risk variants in the human
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population. Effect sizes of trait-associated variants discovered by GWAS are gener-
ally modest (e.g. odds ratio <1.5), conferring relatively small modulation in risk.
In addition, GWAS variants only explain a fraction of the trait variability, leaving
a large proportion of heritability unexplained (e.g. ∼90% unexplained heritability
for coronary artery disease (CARDIoGRAMplusC4D Consortium et al., 2013)). Fi-
nally, some of the largest GWA studies to date typically investigate European-only
populations, leaving complex trait genetics in non-Europeans less well understood.
Because rare variants are not captured well by GWAS with imputation, the role
of rare variants in complex traits is still largely unknown. More comprehensive scans
involving whole-genome or exome sequencing are promising for revealing rare risk
variants that may explain more of the missing heritability. For early-onset diseases
that are rare and highly-penetrant, the missing heritability will likely be found with
extremely low frequency variants of high effect. Although SNP genotyping coupled
with imputation is still more cost-effective today than whole-genome sequencing
(Yang et al., 2015), rare variants can be difficult to impute. This makes a strong
case for sequencing studies in diseases where rare variants are more likely to play a
role.
For more common diseases such as CAD however, the remaining missing heri-
tability will likely be found in common variants with small effects. Ongoing efforts
in genotyping thousands of unrelated individuals on exome chip are revealing more
coding variants with a role in modulation of lipid levels. Meta-analyses of large
non-European populations are currently underway, leading us to new discoveries of
population-specific variants associated with lipids that may not be significant in Eu-
ropeans. Fine mapping of lipid-associated loci in ethnically diverse groups will be
increasingly important to provide guidance toward identifying the causal variant.
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Complex traits and diseases can have variable genetic architectures, making study
design and results interpretation challenging. For example, it is possible that not all
carriers of an associated risk variant will display manifestation of the trait or disease,
suggesting genetic or environmental factors that confer resistance. In addition, some
genetic variants may depend on pre-existing environmental contexts, resulting in
context-dependent risk variants that don’t pass genome wide significance. For heart
disease in particular, these factors could include lifestyle elements such as smoking,
diet, physical activity, or sudden high-stress events (Peters et al., 2014; Chan et al.,
2013). Another caveat of a case-control GWAS design is that disease processes
might be active in control individuals, but the clinical symptoms may have not yet
manifested when they participate in the study. In this case, having a sufficiently
large number of controls or re-evaluating and assigning control individuals at a later
stage will improve the study.
An undisputed challenge in complex trait genetics is the interpretation of noncod-
ing variation. In Chapter III, I presented a practical tool for researchers to investigate
the biological mechanisms of GWAS signals for any phenotype and provide guidance
toward prioritizing the functional variant using epigenomic features. However, there
is still progress to be made in methods for refining the association signal to predict
functional variants and in understanding the mechanisms by which they act. An
improvement over prioritizing variants solely based on the number of overlapping
regulatory features could be assigning variants a score based on their likelihood of
being functional. This score could involve weighting by effect size or the presence
of a nearby motif, or be analogous to the SVM classifier used for filtering variants
from sequencing data. In addition, we can use Bayes theorem to determine the
likelihood of disease-causing SNPs based on prior probability (Maller et al., 2012).
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Integrating other sources of information including functional genomics, chromatin
states, evolutionary conservation, and quantitative trait loci to link noncoding se-
quence with regulation will also be supportive. Burden testing of noncoding variants
is another under-developed area that can shed new insight on transcriptional regula-
tion. Without a doubt, the future progress in understanding the noncoding genetic
variation implicated in complex disease will rely on the coupling of GWAS findings
with cell-type specific sequencing-based functional genomics data.
There is still debate in the genetics community about the clinical implications
of various plasma lipids. In particular, genetic studies describing the causal role of
triglycerides and HDL cholesterol in heart disease risk have contradicted previous
assumptions. In a companion paper published with the results from Global Lipids
Genetics Consortium et al. (2013), causality was established between triglycerides
and coronary artery disease risk through correlation of effect sizes of trait-associated
SNPs (Do et al., 2013). In addition, the study presented by Voight et al. (2012b)
concluded no relationship between HDL-C and risk of heart attack. These two impor-
tant papers have drawn considerable attention from the medical community, and give
direction and/or caution to physicians when considering triglycerides or HDL-C in
disease risk. Advances over traditional approaches of Mendelian randomization that
address the pleiotropy complicating these variants have helped support the causality
of triglycerides on heart disease risk, and can perhaps shed light on the relationships
of other traits and disorders in the future (Burgess and Thompson, 2015).
Given our limited understanding of pharmacogenetics and the effect that indi-
vidual genotypic variation plays in drug response, studies of complex trait genetics
are extremely relevant. An example illustrating the importance of improved phar-
macogenetics understanding is the impaired ability of carriers of CYP2C19 variants
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to metabolize the drug clopidogrel, increasing their risk for heart disease (Kaufman
et al., 2015).
5.3 Data integration and bioinformatics challenges
As we progress in our understanding of complex traits, a major theme emerg-
ing is data integration. Investigators are increasingly collaborating to build large
repositories of high-throughput genomics and epigenomics data for public use. This
openness encourages integrative analyses and presents more creative ways to address
hypotheses. As illustrated in Chapter III, combining GWAS findings with ENCODE
epignomic data can lead to mechanistic insights. Another example of a data-rich
repository is the Genotype-Tissue Expression (GTEx) Portal, which contains nor-
malized expression matrices from RNA-seq in a wide range of human tissues (GTEx
Consortium, 2015). These data can help answer ongoing questions about the non-
coding variation that likely acts through regulation of gene expression. The systems
genetics approach, or Genome Wide Network Study as coined by Bjo¨rkegren et al.
(2015), puts emphasis on combining data from intermediate phenotypes such as
RNA, proteins, metabolites, and epigenetics in multiple disease-relevant tissues. To-
gether, the data generated by these and many other ongoing efforts will surely help fill
in some of the missing knowledge concerning the biological mechanisms underlying
trait-associated genetic variation.
The meta-analysis performed in Chapter II is one of many ongoing and future
collaborations that will rely heavily on data sharing. As scientists increasingly share
their data in public domains, there is a need for more consistent standards in data
formats and metadata annotation. Future genetic studies involving common complex
diseases that rely on large sample sizes will be particularly affected by the data
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sharing and dissemination practices of the larger scientific community. In addition,
large-scale studies of human genetic variation require voluntary cooperation from
the general public. Efforts such as Genes for Good (http://genesforgood.sph.
umich.edu/) utilize social media to collect individual genetic data and educate people
about the personal benefits and larger scientific contributions resulting from their
participation. Data collected in Norway through The HUNT Study (Krokstad et al.,
2013), the source from which data were used in Chapter IV, is an excellent model of
an extensive collection of volunteer-based personal health data. Health informatics
will be increasingly important for optimizing how these large volumes of biomedical
data are managed, stored, shared, and interpreted.
On January 30, 2015, President Obama announced an initiative to transform
healthcare into the era of big data and personalized medicine. The NIH Precision
Medicine Initiative aims to utilize individual risk factors including genetic variability
to develop treatment that is tailored to specific patients. The increasing ubiquity of
mobile devices that record health-related measures such as heart rate, calorie con-
sumption, and physical activity is revolutionizing the way we can monitor health,
reduce risk, and treat disease based on individual lifestyle. Research involving com-
plex trait genetics such as the work presented in this dissertation provides primary
foundational knowledge for facilitating the translation from ‘bench-to-bedside’ and
fulfilling this vision of personalized medicine.
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